AGREEMENT AND PLAN OF MERGER
AGREEMENT AND PLAN OF MERGER
among
JLL PHARMANET HOLDINGS, LLC,
PDGI ACQUISITION CORP.
and
PHARMANET DEVELOPMENT GROUP, INC.
Dated as of February 3, 2009
TABLE OF CONTENTS
Pages
ARTICLE I THE OFFER AND THE MERGER |
2 | |||||||||||
Section 1.1 The Offer |
2 | |||||||||||
Section 1.2 Company Actions |
4 | |||||||||||
Section 1.3 Directors |
5 | |||||||||||
Section 1.4 The Merger |
7 | |||||||||||
Section 1.5 Meeting of Stockholders to Approve the Merger |
9 | |||||||||||
Section 1.6 Merger Without Meeting of Stockholders |
10 | |||||||||||
Section 1.7 Top-Up Option |
10 | |||||||||||
ARTICLE II
CONVERSION OF SHARES IN THE MERGER; EXCHANGE OF CERTIFICATES |
11 | |||||||||||
Section 2.1 Effect on Capital Stock |
11 | |||||||||||
Section 2.2 Exchange of Certificates |
13 | |||||||||||
Section 2.3 Effect of the Merger on Company Stock Options and RSUs |
15 | |||||||||||
ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE COMPANY |
17 | |||||||||||
Section 3.1 Qualification, Organization, etc. |
17 | |||||||||||
Section 3.2 Capital Stock |
19 | |||||||||||
Section 3.3 Subsidiaries |
19 | |||||||||||
Section 3.4 Corporate Authority Relative to This Agreement; No Violation |
20 | |||||||||||
Section 3.5 Reports and Financial Statements |
21 | |||||||||||
Section 3.6 No Undisclosed Liabilities |
22 | |||||||||||
Section 3.7 Compliance with Law; Permits |
22 | |||||||||||
Section 3.8 Environmental Laws and Regulations |
22 | |||||||||||
Section 3.9 Employee Benefit Plans |
24 | |||||||||||
Section 3.10 Interested Party Transactions |
26 | |||||||||||
Section 3.11 Absence of Certain Changes or Events |
26 | |||||||||||
Section 3.12 Litigation |
26 | |||||||||||
Section 3.13 Offer Documents; Schedule 14D-9; Proxy Statement |
26 | |||||||||||
Section 3.14 Tax Matters |
27 | |||||||||||
Section 3.15 Labor Matters; Employment Agreements |
28 | |||||||||||
Section 3.16 Intellectual Property |
29 | |||||||||||
Section 3.17 Property |
29 | |||||||||||
Section 3.18 Required Vote of the Company Stockholders |
30 | |||||||||||
Section 3.19 Material Contracts |
30 | |||||||||||
Section 3.20 Finders or Brokers |
32 | |||||||||||
Section 3.21 State Takeover Statutes |
32 | |||||||||||
Section 3.22 Rights Agreement |
32 | |||||||||||
Section 3.23 Insurance |
32 | |||||||||||
Section 3.24 Foreign Corrupt Practices Act |
33 |
-i-
Pages
ARTICLE IV REPRESENTATIONS AND WARRANTIES OF PARENT AND THE PURCHASER |
33 | |||||||||||
Section 4.1 Qualification; Organization |
33 | |||||||||||
Section 4.2 Corporate Authority Relative to This Agreement; No Violation |
33 | |||||||||||
Section 4.3 Offer Documents; Proxy Statement |
34 | |||||||||||
Section 4.4 Sufficiency of Funds |
35 | |||||||||||
Section 4.5 Ownership and Operations of the Purchaser |
35 | |||||||||||
Section 4.6 Finders or Brokers |
35 | |||||||||||
Section 4.7 Litigation |
36 | |||||||||||
Section 4.8 Solvency |
36 | |||||||||||
Section 4.9 No Other Information |
36 | |||||||||||
Section 4.10 Access to Information; Disclaimer |
36 | |||||||||||
ARTICLE V COVENANTS AND AGREEMENTS |
37 | |||||||||||
Section 5.1 Conduct of Business |
37 | |||||||||||
Section 5.2 No Solicitation |
40 | |||||||||||
Section 5.3 Employee Matters; Equity Awards |
44 | |||||||||||
Section 5.4 Required Approvals |
45 | |||||||||||
Section 5.5 Takeover Statute |
47 | |||||||||||
Section 5.6 Public Announcements |
47 | |||||||||||
Section 5.7 Indemnification and Insurance |
48 | |||||||||||
Section 5.8 Access; Confidentiality |
49 | |||||||||||
Section 5.9 Notification of Certain Matters |
49 | |||||||||||
Section 5.10 Rule 16b-3 |
50 | |||||||||||
Section 5.11 Control of Operations |
50 | |||||||||||
Section 5.12 Certain Transfer Taxes |
50 | |||||||||||
Section 5.13 Obligations of the Purchaser |
50 | |||||||||||
Section 5.14 Rule 14d-10(d) Matters |
50 | |||||||||||
Section 5.15 Certain Professional Advisory Fees, etc. |
51 | |||||||||||
Section 5.16 ISRA |
51 | |||||||||||
Section 5.17 Fundamental Change Notice; Convertible Note Xxxxxxxxxx |
00 | |||||||||||
ARTICLE VI CONDITIONS TO CONSUMMATION OF THE MERGER |
51 | |||||||||||
Section 6.1 Conditions to Each Party Under This Agreement |
51 | |||||||||||
ARTICLE VII TERMINATION |
52 | |||||||||||
Section 7.1 Termination or Abandonment |
52 | |||||||||||
Section 7.2 Termination Fees |
54 | |||||||||||
ARTICLE VIII MISCELLANEOUS |
55 | |||||||||||
Section 8.1 No Survival of Representations and Warranties |
55 | |||||||||||
Section 8.2 Expenses |
55 | |||||||||||
Section 8.3 Counterparts; Effectiveness |
55 |
-ii-
Pages
Section 8.4 Governing Law |
56 | |||||||||||
Section 8.5 Jurisdiction; Enforcement |
56 | |||||||||||
Section 8.6 WAIVER OF JURY TRIAL |
56 | |||||||||||
Section 8.7 Notices |
57 | |||||||||||
Section 8.8 Assignment; Binding Effect |
58 | |||||||||||
Section 8.9 Severability |
58 | |||||||||||
Section 8.10 Entire Agreement; No Third-Party Beneficiaries |
59 | |||||||||||
Section 8.11 Amendments; Waivers |
59 | |||||||||||
Section 8.12 Headings |
59 | |||||||||||
Section 8.13 Interpretation |
59 | |||||||||||
Section 8.14 Certain Definitions |
60 | |||||||||||
ANNEX A CONDITIONS TO THE OFFER |
1 |
-iii-
AGREEMENT AND PLAN OF MERGER, dated as of February 3, 2009 (this “Agreement”), among
JLL PHARMANET HOLDINGS, LLC, a Delaware limited liability company (the “Parent”), PDGI
ACQUISITION CORP., a Delaware corporation and a wholly owned subsidiary of Parent (the
“Purchaser“), and PHARMANET DEVELOPMENT GROUP, INC., a Delaware corporation (the
“Company”). Capitalized terms used herein have the meanings ascribed to them in Section
8.14.
W I T N E S S E T H:
WHEREAS, the board of managers of Parent and the respective boards of directors of the
Purchaser and the Company have approved this Agreement and the acquisition of the Company by Parent
upon the terms and subject to the conditions set forth in this Agreement;
WHEREAS, pursuant to this Agreement, the Purchaser has agreed to commence a tender offer (the
“Offer”) to purchase all of the outstanding shares of the common stock, par value $0.001,
of the Company (the “Company Common Stock”), including the associated preferred share
purchase rights (the “Company Rights”) issued pursuant to the Rights Agreement, dated as of
December 21, 2005, between the Company and American Stock Transfer & Trust Company, as
successor-in-interest to Wachovia Bank, N.A., as Rights Agent (the “Rights Agreement”)
(which Company Rights, together with the shares of the Company Common Stock, are hereinafter
referred to as the “Shares”), at a price per Share of $5.00 (such amount or any different
amount per Share that may be paid pursuant to the Offer, the “Offer Price”), payable net to
the seller in cash, without interest, subject to any withholding of Taxes required by applicable
Law;
WHEREAS, following the acceptance for payment of Shares pursuant to the Offer, upon the terms
and subject to the conditions set forth in this Agreement, the Purchaser will be merged with and
into the Company, with the Company continuing as the Surviving Corporation (the “Merger”),
in accordance with the General Corporation Law of the State of Delaware (the “DGCL”),
whereby each issued and outstanding Share (other than Cancelled Shares and Dissenting Shares) will
be converted into the right to receive the Offer Price, payable net to the holder in cash, without
interest, subject to any withholding of Taxes required by applicable Law;
WHEREAS, the board of directors of the Company (the “Board of Directors”) has, upon
the terms and subject to the conditions set forth herein, (i) determined that the transactions
contemplated by this Agreement, including the Offer and the Merger, are advisable and in the best
interests of the Company and its stockholders, (ii) approved and declared advisable this Agreement
and the transactions contemplated hereby, including the Offer and the Merger, and (iii) recommended
that the Company’s stockholders accept the Offer, tender their Shares to the Purchaser in the Offer
and, to the extent applicable, adopt this Agreement and approve the Merger (the
“Recommendation”); and
WHEREAS, Parent, the Purchaser and the Company desire to make certain representations,
warranties, covenants and agreements in connection with the Offer, the Merger and the other
transactions contemplated by this Agreement and also to prescribe certain conditions to the Offer
and the Merger as specified herein.
NOW, THEREFORE, in consideration of the foregoing and the representations, warranties,
covenants and agreements contained herein, and intending to be legally bound hereby, Parent, the
Purchaser and the Company hereby agree as follows:
ARTICLE I
THE OFFER AND THE MERGER
THE OFFER AND THE MERGER
Section
1.1 The Offer.
(a) As promptly as practicable (and in any event within seven (7) Business Days) after the
date hereof, the Purchaser shall (and Parent shall cause the Purchaser to) commence, within the
meaning of Rule 14d-2 under the Securities Exchange Act of 1934, as amended, and the rules and
regulations promulgated thereunder (the “Exchange Act”), the Offer to purchase all the
outstanding Shares at the Offer Price, subject to: (i) there being validly tendered in the Offer
and not properly withdrawn prior to the Expiration Date that number of Shares which, together with
the number of Shares (if any) then owned of record by Parent or the Purchaser or with respect to
which Parent or the Purchaser otherwise has, directly or indirectly, sole voting power, represents
at least a majority of the Shares outstanding (determined on a fully diluted basis) at the
Expiration Date (the “Minimum Condition”); and (ii) the satisfaction, or waiver by Parent
or the Purchaser, of the other conditions and requirements set forth in Annex A.
(b) Subject to the satisfaction of the Minimum Condition and the satisfaction, or waiver by
Parent or the Purchaser, of the other conditions and requirements set forth in Annex A, the
Purchaser shall (and Parent shall cause the Purchaser to) accept for payment and pay for all Shares
validly tendered and not properly withdrawn pursuant to the Offer as promptly as practicable after
the Purchaser is legally permitted to do so under applicable Law. The Offer Price payable in
respect of each Share validly tendered and not properly withdrawn pursuant to the Offer shall be
paid net to the seller in cash, without interest, subject to any withholding of Taxes required by
applicable Law in accordance with Section 2.2(c). In circumstances in which the stockholders of the
Company do not have the right to seek remedies at law or equity, the obligations of Parent and the
Purchaser under this Agreement are material to the Company’s execution of this Agreement and any
failure by Parent or the Purchaser to comply with the terms of this Agreement shall enable the
Company to seek all remedies available at law or equity to it and on behalf of the stockholders.
(c) The Offer shall be made by means of an offer to purchase (the “Offer to Purchase”)
that describes the terms and conditions of the Offer in accordance with this Agreement, including
the Minimum Condition and the other conditions and requirements set forth in Annex A. Parent and
the Purchaser expressly reserve the right, at any time, in their sole discretion, to waive, in
whole or in part, any condition to the Offer or other requirement set forth in Annex A or increase
the Offer Price or to make any other changes in the terms and conditions of the Offer; provided,
however, that unless previously approved by the Company in writing, the Purchaser shall not (i)
decrease the Offer Price, (ii) change the form of consideration payable in the Offer, (iii) reduce
the maximum number of Shares to be purchased in the Offer, (iv) amend or waive the Minimum
Condition, (v) amend any of the other conditions and requirements to the Offer set forth in Annex A
in a manner adverse to the holders of Shares, or (vi) extend the Expiration Date in a manner other
than in accordance with this Agreement.
2
(d) Unless extended in accordance with the terms of this Agreement, the Offer shall expire at
midnight (New York City time) on the date that is twenty (20) Business Days following the
commencement of the Offer (the “Initial Expiration Date”) or, if the Initial Expiration
Date has been extended in accordance with this Agreement, the date on which the Offer has been so
extended (the Initial Expiration Date, or such later date to which the Initial Expiration Date has
been extended in accordance with this Agreement (the “Expiration Date”).
(e) If on or prior to any then scheduled Expiration Date, all of the conditions to the Offer
(including the Minimum Condition and the other conditions and requirements set forth in Annex A)
have not been satisfied, or waived by Parent or the Purchaser, the Purchaser may, in its sole
discretion, without the consent of the Company cause the Purchaser to extend the Offer for
successive periods of up to twenty (20) Business Days each, the length of each such period to be
determined by Parent in its sole discretion, in order to permit the satisfaction of such
conditions. The Purchaser shall extend the Offer for any period or periods required by applicable
Law or applicable rules, regulations, interpretations or positions of the U.S. Securities and
Exchange Commission (the “SEC”) or its staff. Notwithstanding the foregoing, Parent and
the Purchaser agree that if on any scheduled Expiration Date, either the Minimum Condition or the
HSR Condition (as such term is defined in Annex A), is not satisfied but all of the other
conditions and requirements set forth in Annex A are satisfied or, in Parent’s and the Purchaser’s
sole discretion, waived, then the Purchaser shall, and Parent shall cause the Purchaser to, extend
the Offer for up to forty (40) Business Days in the aggregate, the length of such period to be
determined by the Company in its sole discretion; provided, however, that this provision shall not
require the Purchaser to extend the Offer more than twice and the Purchaser shall not be required
to extend the Offer (i) beyond August 15, 2009 (the “Outside Date”), or (ii) at any time
that Parent and the Purchaser have the right to terminate this Agreement pursuant to Article VII.
(f) If necessary to obtain sufficient Shares (without regard to Shares issuable upon the
exercise of the Top-Up Option or Shares tendered pursuant to guaranteed delivery procedures that
have not yet been delivered in settlement or satisfaction of such guarantee) to reach the Short
Form Threshold, the Purchaser may, in its sole discretion, cause the Purchaser to provide for a
“subsequent offering period” (and one or more extensions thereof) in accordance with Rule 14d-11
under the Exchange Act of up to twenty (20) Business Days. Subject to the terms and conditions of
this Agreement and the Offer, the Purchaser shall (and Parent shall cause the Purchaser to)
immediately accept for payment, and pay for, all Shares that are validly tendered pursuant to the
Offer during such “subsequent offering period”. The Offer Documents will provide for the
possibility of a “subsequent offering period” in a manner consistent with the terms of this Section
1.1(f).
(g) The Purchaser shall not terminate the Offer prior to any scheduled Expiration Date without
the prior written consent of the Company, except if this Agreement is terminated pursuant to
Article VII. If this Agreement is terminated pursuant to Article VII, the Purchaser shall (and
Parent shall cause the Purchaser to) promptly (and in any event within twenty-four (24) hours of
such termination), irrevocably and unconditionally terminate the Offer. If the Offer is terminated
or withdrawn by the Purchaser, or this Agreement is terminated prior to the purchase of Shares in
the Offer, the Purchaser shall promptly return, and shall cause any depositary acting on behalf of
the Purchaser to return, in accordance with applicable Law, all tendered Shares to the registered
holders thereof.
3
(h) As soon as practicable on the date of the commencement of the Offer, Parent and the
Purchaser shall file with the SEC, in accordance with Rule 14d-3 under the Exchange Act, a Tender
Offer Statement on Schedule TO with respect to the Offer (together with all amendments, supplements
and exhibits thereto, the “Schedule TO”). The Schedule TO shall include, as exhibits, the
Offer to Purchase, a form of letter of transmittal and a form of summary advertisement
(collectively, together with any amendments and supplements thereto, the “Offer
Documents”). Parent and the Purchaser agree to cause the Offer Documents to be disseminated to
holders of Shares, as and to the extent required by the Exchange Act. Parent and the Purchaser, on
the one hand, and the Company, on the other hand, agree to promptly correct any information
provided by it for use in the Offer Documents, if and to the extent that such information shall
have become false or misleading in any material respect or as otherwise required by applicable Law,
and Parent and the Purchaser agree to cause the Offer Documents, as so corrected, to be filed with
the SEC and disseminated to holders of Shares, in each case as and to the extent required by the
Exchange Act. The Company and its counsel shall be given a reasonable opportunity to review the
Schedule TO and the Offer Documents before they are filed with the SEC, and Parent and the
Purchaser shall give due consideration to the reasonable additions, deletions or changes suggested
thereto by the Company and its counsel. In addition, Parent and the Purchaser shall provide the
Company and its counsel with copies of any written comments, and shall inform them of any oral
comments, that Parent, the Purchaser or their counsel may receive from time to time from the SEC or
its staff with respect to the Schedule TO or the Offer Documents promptly after receipt of such
comments, and any written or oral responses thereto. The Company and its counsel shall be given a
reasonable opportunity to review any such written responses and Parent and the Purchaser shall give
due consideration to the reasonable additions, deletions or changes suggested thereto by the
Company and its counsel. In the event that Parent and the Purchaser receive any comments from the
SEC or its staff with respect to the Schedule TO, they shall use their respective reasonable best
efforts to (i) respond promptly to such comments and (ii) take all other actions necessary to
resolve the issues raised therein.
Section
1.2 Company Actions.
The Company hereby approves and consents to the Offer, the Merger and the other transactions
contemplated by this Agreement and represents that the Board of Directors, at a meeting duly called
and held has, subject to Section 5.2(d):
(i) determined that the Offer, the Merger, this Agreement and the transactions contemplated
hereby are advisable and in the best interests of the Company and its stockholders;
(ii) adopted this Agreement and approved the transactions contemplated hereby;
(iii) resolved to recommend acceptance of the Offer and, if required, adoption of this
Agreement and approval of the Merger by its stockholders; and
(iv) taken all other actions necessary to exempt the Offer, the Merger, this Agreement and the
transactions contemplated hereby from any “fair price”, “moratorium”,
4
“control share acquisition”, “interested stockholder”, “business combination” or other similar
statute or regulation (“Takeover Statute”).
(b) Contemporaneous with the filing of the Schedule TO, the Company shall, in a manner that
complies with Rule 14d-9 under the Exchange Act, file with the SEC a Tender Offer
Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the Offer (together with
all amendments, supplements and exhibits thereto, the “Schedule 14D-9”) that shall, subject
to the provisions of Section 5.2(d), contain the Recommendation. The Company hereby consents to
the inclusion in the Offer Documents of a description of the Recommendation. The Company further
agrees to cause the Schedule 14D-9 to be disseminated to holders of Shares, as and to the extent
required by the Exchange Act. The Company, on the one hand, and Parent and the Purchaser, on the
other hand, agree to promptly correct any information provided by it for use in the Schedule 14D-9,
if and to the extent that such information shall have become false or misleading in any material
respect or as otherwise required by applicable Law, and the Company agrees to cause the Schedule
14D-9, as so corrected, to be filed with the SEC and disseminated to holders of Shares, in each
case as and to the extent required by the Exchange Act. Parent, the Purchaser and their counsel
shall be given a reasonable opportunity to review the Schedule 14D-9 before it is filed with the
SEC, and the Company shall give due consideration to the reasonable additions, deletions or changes
suggested thereto by Parent, the Purchaser and their counsel. In addition, the Company shall
provide Parent, the Purchaser and their counsel with copies of any written comments, and shall
inform them of any oral comments, that the Company or its counsel may receive from time to time
from the SEC or its staff with respect to the Schedule 14D-9 promptly after receipt of such
comments, and any written or oral responses thereto. Parent, the Purchaser and their counsel shall
be given a reasonable opportunity to review any such written responses and the Company shall give
due consideration to the reasonable additions, deletions or changes suggested thereto by Parent,
the Purchaser and their counsel. In the event that the Company receives any comments from the SEC
or its staff with respect to the Schedule 14D-9, it shall use its reasonable best efforts to (i)
respond promptly to such comments and (ii) take all other actions necessary to resolve the issues
raised therein.
(c) Promptly after the date hereof and otherwise from time to time as requested by the
Purchaser or its agents, the Company shall furnish or cause to be furnished to the Purchaser
mailing labels, security position listings, non-objecting beneficial owner lists and any other
listings or computer files containing the names and addresses of the record or beneficial holders
of the Shares as of the most recent practicable date, and shall promptly furnish Purchaser with
such information (including updated lists of holders of the Shares and their addresses, mailing
labels, security position listings and non-objecting beneficial owner lists) and such other
assistance as the Purchaser or its agents may reasonably request in communicating with the record
and beneficial holders of Shares in connection with the preparation and dissemination of the
Schedule TO and the Offer Documents and the solicitation of tenders of Shares in the Offer.
Section
1.3 Directors.
(a) After the Purchaser first accepts for payment Shares tendered and not properly withdrawn
pursuant to the Offer, without regard to any “subsequent offering period”
5
(the “Acceptance Time”), and at all times thereafter, Parent shall be entitled to
elect or designate such number of directors, rounded up to the next whole number, on the Board of
Directors as is equal to the product of the total number of directors on the Board of Directors
(giving effect to the directors elected or designated by Parent pursuant to this sentence)
multiplied by the percentage that the aggregate number of Shares beneficially owned by Parent, the
Purchaser or any of their respective Affiliates bears to the total number of Shares then
outstanding. After the Acceptance Time, the Company shall, upon Parent’s reasonable request, take
all actions as are reasonably necessary or desirable to enable Parent’s designees to be so elected
or designated to the Board of Directors, including promptly filling vacancies or newly created
directorships on the Board of Directors, promptly increasing the size of the Board of Directors
(including by amending the By-laws if necessary to increase the size of the Board of Directors)
and/or promptly securing the resignations of such number of its incumbent directors, and shall
cause Parent’s designees to be so elected or designated at such time. After the Acceptance Time,
the Company shall also, upon Parent’s request, cause the directors elected or designated by Parent
to the Board of Directors to serve on and constitute the same percentage (rounded up to the next
whole number) as is on the Board of Directors of (i) each committee of the Board of Directors, (ii)
each board of directors (or similar body) of each Company Subsidiary and (iii) each committee (or
similar body) of each such board, in each case to the extent permitted by applicable Law and the
Marketplace Rules of the Nasdaq Global Select Market (“Nasdaq”). After the Acceptance
Time, the Company shall also, upon Parent’s request, take all action necessary to elect to be
treated as a “controlled company” as defined by Nasdaq Marketplace Rule 4350(c) and make all
necessary filings and disclosures associated with such status. The provisions of this Section
1.3(a) are in addition to and shall not limit any rights that Parent, the Purchaser or any of their
respective Affiliates may have as a record holder or beneficial owner of Shares as a matter of
applicable Law with respect to the election of directors or otherwise.
(b) The Company’s obligations to appoint Parent’s designees to the Board of Directors shall be
subject to Section 14(f) of the Exchange Act and Rule 14f-1 promulgated thereunder. The Company
shall promptly take all actions required pursuant to Section 14(f) and Rule 14f-1 in order to
fulfill its obligations under this Section 1.3(b), including mailing to stockholders (together with
the Schedule 14D-9) any information required by Section 14(f) and Rule 14f-1 to enable Parent’s
designees to be elected or designated to the Board of Directors at the time or times contemplated
by this Section 1.3. Parent shall supply or cause to be supplied to the Company any information
with respect to Parent, the Purchaser, their respective officers, directors and Affiliates and
proposed designees to the Board of Directors required by Section 14(f) and Rule 14f-1.
(c) After Parent’s designees are elected or designated to, and constitute a majority of, the
Board of Directors pursuant to Section 1.3(a), and prior to the Effective Time, the Company shall
cause the Board of Directors to maintain at least three (3) directors who are members of the Board
of Directors on the date hereof, each of whom shall be an “independent director” as defined by Rule
4200(a)(15) of the Nasdaq Marketplace Rules and eligible to serve on the Company’s audit committee
under the Exchange Act and Nasdaq rules and at least one of whom shall be an “audit committee
financial expert” as defined in Item 401(h) of Regulation S-K and the instructions thereto (the
“Continuing Directors”); provided, however, that if any Continuing Director is unable to
serve due to death, disability or resignation, the Company shall take all necessary action
(including creating a committee of the Board of Directors) so that the
6
remaining Continuing Director or Continuing Directors shall be entitled to elect or designate
another Person who satisfies the foregoing independence requirements to fill such vacancy, and such
Person shall be deemed to be a Continuing Director for purposes of this Agreement. After Parent’s
designees are elected or designated to, and constitute a majority of, the Board of Directors
pursuant to Section 1.3(a), and prior to the Effective Time, in addition to any approvals of the
Board of Directors or the stockholders of the Company as may be required by the Company Charter,
the By-laws or applicable Law, any (i) amendment or modification of this Agreement, (ii)
termination of this Agreement by the Company, (iii) extension of time for performance of any of the
obligations of Parent or the Purchaser hereunder, (iv) waiver of any condition to the Company’s
obligation hereunder, (v) exercise or waiver of the Company’s rights or remedies hereunder, (vi)
amendment to the Company Charter or the By-laws, (vii) authorization of any agreement between the
Company and any of its Subsidiaries, on the one hand, and Parent, the Purchaser or any of their
Affiliates on the other hand, or (viii) taking of any other action by the Company in connection
with this Agreement or the transactions contemplated hereby may, in each case, be effected only if
there are in office one (1) or more Continuing Directors and such action is approved by a majority
of the Continuing Directors then in office; provided, however, that the Company shall designate,
prior to the Acceptance Time, two (2) alternate Continuing Directors that the Board of Directors
shall appoint in the event of the death, disability or resignation of the Continuing Directors,
each of whom shall, following such appointment to the Board of Directors, be deemed to be a
Continuing Director for purposes of this Agreement. The Continuing Directors shall have, and Parent
shall cause the Continuing Directors to have, the authority to retain such counsel (which may
include current counsel to the Company or the Board of Directors) and other advisors at the expense
of the Company as determined by the Continuing Directors, and the authority to institute any action
on behalf of the Company to enforce performance of this Agreement.
Section
1.4 The Merger.
(a) At the Effective Time, upon the terms and subject to the conditions set forth in this
Agreement and in accordance with the applicable provisions of the DGCL, the Purchaser shall be
merged with and into the Company, whereupon the separate corporate existence of the Purchaser shall
cease, and the Company shall continue as the surviving corporation in the Merger (the
“Surviving Corporation”) and a wholly owned subsidiary of Parent.
(b) The closing of the Merger (the “Closing”) shall take place at the offices of
Skadden, Arps, Slate, Xxxxxxx & Xxxx LLP, Four Times Square, New York, New York at 10:00 a.m.,
local time, on the date (the “Closing Date”) that is the third (3rd) Business
Day following the satisfaction or waiver (to the extent permitted by applicable Law) of the
conditions set forth in Article VI (other than those conditions that by their nature are to be
satisfied at the Closing, but subject to the satisfaction or waiver of such conditions at the
Closing) or on such other date and time as specified by the parties in writing.
(c) On the Closing Date, the Company shall cause the Merger to be consummated by executing,
delivering and filing the Certificate of Merger (the “Certificate of Merger”) with the
Secretary of State of the State of Delaware in accordance with the relevant provisions of the DGCL
and other applicable Delaware Law. The Merger shall become effective
7
at such time as the Certificate of Merger is duly filed with the Secretary of State of the
State of Delaware, or at such later date or time as may be agreed by Parent and the Company in
writing and specified in the Certificate of Merger in accordance with the DGCL (such time as the
Merger becomes effective is referred to herein as the “Effective Time”).
(d) The Merger shall have the effects set forth in this Agreement and the applicable
provisions of the DGCL.
(e) The Certificate of Incorporation of the Company as amended (the “Company Charter”)
shall, by virtue of the Merger, be amended and restated in its entirety to read as the Certificate
of Incorporation of the Purchaser as in effect as of immediately prior to the Effective Time,
except that Article I thereof shall read as follows: “The name of the Corporation is PharmaNet
Development Group, Inc.” and, as so amended, shall be the Certificate of Incorporation of the
Surviving Corporation until thereafter amended in accordance with the provisions thereof, hereof
and of applicable Law, in each case consistent with the obligations set forth in Section 5.7.
(f) The by-laws of the Purchaser, as in effect as of immediately prior to the Effective Time,
shall, by virtue of the Merger, be the by-laws of the Surviving Corporation until thereafter
amended in accordance with the provisions thereof, hereof and of applicable Law, in each case
consistent with the obligations set forth in Section 5.7.
(g) The directors of the Purchaser as of immediately prior to the Effective Time shall be the
initial directors of the Surviving Corporation and shall hold office until their respective
successors are duly elected and qualified, or their earlier death, resignation or removal.
(h) The officers of the Company as of immediately prior to the Effective Time shall be the
initial officers of the Surviving Corporation and shall hold office until their respective
successors are duly elected and qualified, or their earlier death, resignation or removal.
(i) If at any time after the Effective Time the Surviving Corporation shall consider or be
advised that any deeds, bills of sale, assignments or assurances or any other acts or things are
necessary, desirable or proper (a) to vest, perfect or confirm, of record or otherwise, in the
Surviving Corporation its right, title or interest in, to or under any of the rights, privileges,
powers, franchises, properties or assets of either the Purchaser or the Company, or (b) otherwise
to carry out the purposes of this Agreement, the Surviving Corporation and its proper officers and
directors or their designees shall be authorized to execute and deliver, in the name and on behalf
of either of the Purchaser or the Company, all such deeds, bills of sale, assignments and
assurances and to do, in the name and on behalf of either the Purchaser or the Company, all such
other acts and things as may be necessary, desirable or proper to vest, perfect or confirm the
Surviving Corporation’s right, title or interest in, to or under any of the rights, privileges,
powers, franchises, properties or assets of the Purchaser or the Company and otherwise to carry out
the purposes of this Agreement.
8
Section
1.5 Meeting of Stockholders to Approve the Merger.
(a) If the adoption of this Agreement by the stockholders of the Company is required under the
DGCL, then as promptly as practicable after the Acceptance Time, the Company shall prepare and file
with the SEC, print and mail to the stockholders of the Company a proxy statement or information
statement for the Company Meeting (together with any amendments and supplements thereto, the letter
to stockholders, notice of meeting, forms of proxy and any other soliciting materials to be
distributed to stockholders in connection with the Merger, the “Proxy Statement.”) relating
to the Merger and this Agreement. Parent and the Purchaser will use their reasonable best efforts
to supply information necessary for the Proxy Statement, if any, as promptly as practicable after
the Acceptance Time. Parent, the Purchaser and their counsel shall be given a reasonable
opportunity to review the Proxy Statement before it is filed with the SEC, and the Company shall
give due consideration to the reasonable additions, deletions or changes suggested thereto by
Parent, the Purchaser and their counsel. The Company shall include the Recommendation in the Proxy
Statement. The Company, on the one hand, and Parent and the Purchaser, on the other hand, agree to
promptly correct any information provided by it for use in the Proxy Statement, if and to the
extent that such information shall have become false or misleading in any material respect or as
otherwise required by applicable Law, and the Company agrees to cause the Proxy Statement, as so
corrected, to be filed with the SEC and, if any such correction is made following the mailing of
the Proxy Statement, mailed to holders of Shares, in each case as and to the extent required by the
Exchange Act. The Company shall provide Parent, the Purchaser and their counsel with copies of any
written comments, and shall inform them of any oral comments, that the Company or its counsel may
receive from time to time from the SEC or its staff with respect to the Proxy Statement promptly
after the Company’s receipt of such comments, and any written or oral responses thereto. Parent,
the Purchaser and their counsel shall be given a reasonable opportunity to review any such written
responses and the Company shall give due consideration to the reasonable additions, deletions or
changes suggested thereto by Parent, the Purchaser and their counsel. In the event that the
Company receives any comments from the SEC or its staff with respect to the Proxy Statement, it
shall use its reasonable best efforts to (i) respond promptly to such comments and (ii) take all
other actions necessary to resolve the issues raised therein.
(b) If the adoption of this Agreement by the stockholders of the Company is required under the
DGCL, the Company, acting through the Board of Directors, shall, in accordance with and subject to
the requirements of applicable Law: (i) as promptly as practicable after the Acceptance Time, in
consultation with Parent, duly set a record date for, call and give notice of a special meeting of
its stockholders (such meeting or any adjournment or postponement thereof, the “Company
Meeting”) for the purpose of considering and taking action upon this Agreement (with the record
date to be set in consultation with Parent for a date after the Acceptance Time); (ii) as promptly
as practicable after the Acceptance Time, but in any event within thirty (30) days thereafter, file
the Proxy Statement with the SEC, cause the Proxy Statement to be printed and mailed to the
stockholders of the Company and convene and hold the Company Meeting; and (iii) use its reasonable
best efforts to solicit from its stockholders proxies in favor of the adoption of this Agreement
and approval of the Merger, and secure any approval of stockholders of the Company that is required
by applicable Law to effect the Merger.
9
(c) At the Company Meeting or any postponement or adjournment thereof, Parent shall vote, or
cause to be voted, all of the Shares then owned of record by Parent or the Purchaser or with
respect to which Parent or the Purchaser otherwise has, directly or indirectly, sole voting power
in favor of the adoption of this Agreement and approval of the Merger and to deliver or provide, in
its capacity as a stockholder of the Company, any other approvals that are required by applicable
Law to effect the Merger.
Section
1.6 Merger Without Meeting of Stockholders. Notwithstanding the terms of Section 1.5, if
after the Acceptance Time and, if applicable, the expiration of any “subsequent offering period”
provided by the Purchaser in accordance with this Agreement and/or the exercise of the Top-Up
Option, Parent and the Purchaser shall then hold of record, in the aggregate, at least 90% of the
outstanding Shares (the “Short Form Threshold”), the parties hereto agree to take all necessary and
appropriate action to cause the Merger to become effective as promptly as practicable without a
meeting of stockholders of the Company in accordance with Section 253 of the DGCL.
Section
1.7 Top-Up Option.
(a) The Company hereby grants to the Purchaser an irrevocable option (the “Top-Up
Option”), exercisable once upon the terms and subject to the conditions set forth herein, to
purchase at the Offer Price an aggregate number of Shares (the “Top-Up Shares”) that, when
added to the number of Shares held of record by Parent and the Purchaser at the time of such
exercise, shall constitute at least one (1) Share more than the Short Form Threshold; provided,
however, that in no event shall the Top-Up Option be exercisable for a number of Shares in excess
of the number of authorized but unissued Shares as of immediately prior to the issuance of the
Top-Up Shares (giving effect to Shares reserved for issuance under the Company Equity Plans and the
Company’s 2.25% Convertible Senior Notes Due 2024 (the “Convertible Notes”) as if such
Shares were outstanding); provided further, that the Top-Up Option shall terminate upon the earlier
of: (x) the fifth (5th) Business Day after the later of (1) the Expiration Date and (2) the
expiration of any “subsequent offering period”; and (y) the termination of this Agreement in
accordance with its terms.
(b) The obligation of the Company to deliver Top-Up Shares upon the exercise of the Top-Up
Option is subject to the conditions that (i) no provision of any applicable law and no Order shall
prohibit the exercise of the Top-Up Option or the delivery of the Top-Up Shares in respect of such
exercise, (ii) upon exercise of the Top-Up Option, the number of Shares held of record by Parent
and the Purchaser constitutes at least one (1) Share more than ninety percent (90%) of the number
of Shares that shall be outstanding immediately after the issuance of the Top-Up Shares, and (iii)
the Purchaser has accepted for payment all Shares validly tendered in the Offer and not properly
withdrawn. The parties shall cooperate to ensure that the issuance of the Top-Up Shares is
accomplished consistent with all applicable legal requirements of all Governmental Entities,
including compliance with an applicable exemption from registration of the Top-Up Shares under the
Securities Act.
(c) To exercise the Top-Up Option, the Purchaser shall send to the Company a written notice (a
“Top-Up Exercise Notice”) specifying (i) the number of Shares that shall be held of record
by Parent and the Purchaser immediately preceding the purchase of the Top-Up
10
Shares and (ii) the place, time and date for the closing of the purchase and sale of the
Top-Up Shares (the “Top-Up Closing”). The Company shall, promptly after receipt of the
Top-Up Exercise Notice, deliver a written notice to the Purchaser confirming the number of Top-Up
Shares and the aggregate purchase price therefor (the “Top-Up Notice Receipt”). At the
Top-Up Closing, the Purchaser shall pay the Company, in the manner set forth in Section 1.7(d)
hereof, the aggregate price required to be paid for the Top-Up Shares, in an aggregate principal
amount equal to that specified in the Top-Up Notice Receipt, and the Company shall cause to be
issued and delivered to the Purchaser a certificate or certificates representing the Top-Up Shares
or, at the Purchaser’s request or otherwise if the Company does not then have certificated Shares,
the applicable number of Book-Entry Shares. Such certificates or Book-Entry Shares may include any
legends that are required by applicable Law.
(d) The Purchaser may pay the Company the aggregate price required to be paid for the Top-Up
Shares either (i) entirely in cash or (ii) at the Purchaser’s election, by (x) paying in cash an
amount equal to not less than the aggregate par value of the Top-Up Shares and (y) executing and
delivering to the Company a promissory note having a principal amount equal to the balance of the
aggregate purchase price pursuant to the Top-Up Option less the amount paid in cash pursuant to the
preceding clause (x) (a “Promissory Note”). Any such Promissory Note shall be full
recourse against Parent and the Purchaser and (i) shall bear interest at the rate of 3% per annum,
(ii) shall mature on the first (1st) anniversary of the date of execution and delivery
of such Promissory Note and (iii) may be prepaid, in whole or in part, without premium or penalty.
(e) Parent and the Purchaser acknowledge that the Top-Up Shares which the Purchaser may
acquire upon exercise of the Top-Up Option shall not be registered under the Securities Act and
shall be issued in reliance upon an exemption for transactions not involving a public offering.
Parent and the Purchaser represent and warrant to the Company that the Purchaser is, or shall be
upon any purchase of Top-Up Shares, an “accredited investor”, as defined in Rule 501 of Regulation
D under the Securities Act. The Purchaser agrees that the Top-Up Option, and the Top-Up Shares to
be acquired upon exercise of the Top-Up Option, if any, are being and shall be acquired by the
Purchaser for the purpose of investment and not with a view to, or for resale in connection with,
any distribution thereof (within the meaning of the Securities Act).
ARTICLE II
CONVERSION OF SHARES IN THE MERGER; EXCHANGE OF CERTIFICATES
CONVERSION OF SHARES IN THE MERGER; EXCHANGE OF CERTIFICATES
Section
2.1 Effect on Capital Stock. At the Effective Time, by virtue of the Merger and without
any action on the part of the Company, Parent, the Purchaser or the holders of any securities of
the Company, Parent or the Purchaser:
(a) Conversion of Company Common Stock.
(i) Subject to Section 2.1(b) and Section 2.1(d), each issued and outstanding Share other than
(i) any Shares (the “Dissenting Shares”) that are owned by stockholders (the
“Dissenting Stockholders”) properly exercising appraisal rights pursuant to Section 262 of
the DGCL, and (ii) any Cancelled Shares (as defined, and to the extent provided,
11
in Section 2.1(b)), shall thereupon be converted automatically into and shall thereafter
represent the right to receive the Offer Price (the “Merger Consideration”), payable net to
the holder in cash, without interest, subject to any withholding of Taxes required by applicable
Law in accordance with Section 2.2(c).
(ii) All Shares that have been converted into the right to receive the Merger Consideration as
provided in this Section 2.1 shall be automatically cancelled and shall cease to exist, and the
holders of certificates which immediately prior to the Effective Time represented such Shares shall
cease to have any rights with respect to such Shares other than the right to receive the Merger
Consideration in accordance with Section 2.2.
(b) Parent, Purchaser and Company-Owned Shares. Each Share that is owned, directly or
indirectly, by Parent or the Purchaser immediately prior to the Effective Time, if any, or held by
the Company immediately prior to the Effective Time (in each case, other than any such Shares held
on behalf of third parties or Shares held in trust to fund Company obligations) (the “Cancelled
Shares”) shall, by virtue of the Merger and without any action on the part of the holder
thereof, be cancelled and retired and shall cease to exist, and no consideration shall be delivered
in exchange for such cancellation and retirement.
(c) Conversion of Purchaser Common Stock. At the Effective Time, by virtue of the
Merger and without any action on the part of the holder thereof, each share of common stock, par
value $0.001 per share, of the Purchaser issued and outstanding immediately prior to the Effective
Time shall be converted into and become one validly issued, fully paid and nonassessable share of
common stock, par value $0.001 per share, of the Surviving Corporation and shall constitute the
only outstanding shares of capital stock of the Surviving Corporation. From and after the
Effective Time, all certificates representing the common stock of the Purchaser shall be deemed for
all purposes to represent the number of shares of common stock of the Surviving Corporation into
which they were converted in accordance with the immediately preceding sentence.
(d) Dissenters’ Rights. Any Person who otherwise would be deemed a Dissenting
Stockholder shall not be entitled to receive the Merger Consideration with respect to the Shares
owned by such Person unless and until such Person shall have failed to perfect or shall have
effectively withdrawn or lost such Person’s right to dissent from the Merger under the DGCL. Each
Dissenting Stockholder shall be entitled to receive only the payment provided by Section 262 of the
DGCL with respect to Shares owned by such Dissenting Stockholder. The Company shall give Parent
(i) prompt notice of any written demands for appraisal, attempted withdrawals of such demands, and
any other instruments served pursuant to applicable Law received by the Company relating to
stockholders’ rights of appraisal and (ii) the opportunity to direct all negotiations and
proceedings with respect to demand for appraisal under the DGCL. The Company shall not, except
with the prior written consent of Parent, voluntarily make any payment with respect to any demands
for appraisals of Dissenting Shares, offer to settle or settle any such demands or approve any
withdrawal of any such demands.
12
Section
2.2 Exchange of Certificates.
(a) Paying Agent. At or immediately prior to the Effective Time, Parent shall
deposit, or shall cause to be deposited, with a U.S. bank or trust company that shall be appointed
by Parent and approved in advance by the Company (such approval not to be unreasonably withheld) to
act as a paying agent hereunder (the “Paying Agent”), in trust for the benefit of holders
of the Shares, cash in U.S. dollars sufficient to pay the aggregate Merger Consideration in
exchange for all of the Shares outstanding immediately prior to the Effective Time pursuant to the
provisions of this Article II (such cash being hereinafter referred to as the “Exchange
Fund”).
(b) Payment Procedures.
(i) As soon as reasonably practicable after the Effective Time and in any event not later than
the fifth (5th) Business Day following the Effective Time, the Paying Agent shall mail
to each holder of record of Shares whose Shares were converted into the Merger Consideration
pursuant to Section 2.1, (A) a letter of transmittal which shall specify that delivery shall be
effected, and risk of loss and title to the certificates that immediately prior to the Effective
Time represented Shares (“Certificates”) shall pass, only upon delivery of Certificates to
the Paying Agent (and shall be in such form and have such other provisions as Parent and the
Company may reasonably determine prior to the Effective Time) and (B) instructions for use in
effecting the surrender of Certificates (or effective affidavits of loss in lieu thereof) or
non-certificated Shares represented by book-entry (“Book-Entry Shares”) in exchange for the
Merger Consideration.
(ii) Upon surrender of Certificates (or effective affidavits of loss in lieu thereof) or
Book-Entry Shares to the Paying Agent together with such letter of transmittal, duly completed and
validly executed in accordance with the instructions thereto, and such other documents as may
customarily be required by the Paying Agent, the holder of such Certificates or Book-Entry Shares
shall be entitled to receive in exchange therefor an amount (after giving effect to any required
Tax withholdings) equal to the product of (x) the number of Shares represented by such holder’s
properly surrendered Certificates (or effective affidavits of loss in lieu thereof) and Book-Entry
Shares multiplied by (y) the applicable Merger Consideration. No interest will be paid or accrued
on any amount payable upon due surrender of Certificates or Book-Entry Shares. In the event of a
transfer of ownership of Shares that is not registered in the transfer or stock records of the
Company, any cash to be paid upon due surrender of the Certificate formerly representing such
Shares may be paid to such a transferee if such Certificate is presented to the Paying Agent,
accompanied by all documents required to evidence and effect such transfer and to evidence that any
applicable stock transfer or other similar Taxes have been paid or are not applicable.
(c) Withholding Rights. The Surviving Corporation, Parent, the Purchaser and the
Paying Agent shall be entitled to deduct and withhold from the relevant Offer Price or Merger
Consideration otherwise payable under this Agreement to any Person such amounts as are required to
be withheld or deducted under the Internal Revenue Code of 1986, as amended (the “Code”),
or any other provision of Tax Law with respect to the making of such payment. To the extent that
amounts are so withheld or deducted and paid over to the applicable Governmental Entity, such
withheld or deducted amounts shall be treated for all purposes of this
13
Agreement as having been paid to such Person in respect of which such deduction and
withholding were made.
(d) Closing of Transfer Books. At the Effective Time, the stock transfer books of the
Company shall be closed, and there shall be no further registration of transfers on the stock
transfer books of the Surviving Corporation of the Shares that were outstanding immediately prior
to the Effective Time. If, after the Effective Time, Certificates are presented to the Surviving
Corporation or Parent for transfer, they shall be cancelled and exchanged for the proper amount
pursuant to and subject to the requirements of this Article II.
(e) Termination of Exchange Fund. Any portion of the Exchange Fund (including the
proceeds of any investments thereof) that remains undistributed to the former holders of Shares for
one year after the Effective Time shall be delivered to the Surviving Corporation upon demand, and
any former holders of Shares who have not surrendered their Shares in accordance with this Section
2.2 shall thereafter look only to the Surviving Corporation for payment of their claim for the
Merger Consideration, without any interest thereon, upon due surrender of their Shares.
(f) No Liability. Notwithstanding anything herein to the contrary, none of the
Company, Parent, the Purchaser, the Surviving Corporation, the Paying Agent or any other Person
shall be liable to any former holder of Shares for any amount properly delivered to a public
official pursuant to any applicable abandoned property, escheat or similar Law. If any Certificate
shall not have been surrendered prior to the date on which the related Merger Consideration would,
pursuant to applicable Law, escheat to or become the property of any Governmental Entity, any such
Merger Consideration shall, to the extent permitted by applicable Law, immediately prior to such
time, become the property of the Surviving Corporation, free and clear of all claims or interests
of any Person previously entitled thereto.
(g) Investment of Exchange Fund. The Paying Agent shall invest all cash included in
the Exchange Fund as reasonably directed by Parent; provided, however, that any investment of such
cash shall in all events be limited to direct short-term obligations of, or short-term obligations
fully guaranteed as to principal and interest by, the U.S. government, in commercial paper rated
A-1 or P-1 or better by Xxxxx’x Investors Service, Inc. or Standard & Poor’s Corporation,
respectively, or in certificates of deposit, bank repurchase agreements or banker’s acceptances of
commercial banks with capital exceeding $10 billion (based on the most recent financial statements
of such bank that are then publicly available), and that no such investment or loss thereon shall
affect the amounts payable to holders of Certificates or Book-Entry Shares pursuant to this Article
II. Any interest and other income resulting from such investments shall be paid to the Surviving
Corporation on the earlier of one year after the Effective Time or full payment of the Exchange
Fund.
(h) Lost Certificates. In the case of any Certificate that has been lost, stolen or
destroyed, upon the making of an affidavit, in form and substance reasonably acceptable to Parent,
of that fact by the Person claiming such Certificate to be lost, stolen or destroyed and, if
required by Parent or the Paying Agent, the posting by such Person of an indemnity agreement or, at
the election of Parent or the Paying Agent, a bond in customary amount as indemnity against any
claim that may be made against it or the Surviving Corporation with respect to such
14
Certificate, the Paying Agent will deliver in exchange for such lost, stolen or destroyed
Certificate an amount in cash equal to the number of Shares represented by such lost, stolen or
destroyed Certificate multiplied by the Merger Consideration.
(i) No Further Ownership Rights. All cash paid upon the surrender of Certificates in
accordance with the terms of this Article II shall be deemed to have been paid in full satisfaction
of all rights pertaining to the Shares formerly represented by such Certificates.
Section
2.3 Effect of the Merger on Company Stock Options and RSUs. Except for Company Stock
Options and RSUs as to which the treatment in the Merger is hereafter separately agreed by Parent
and the holder thereof, which Company Stock Options and RSUs shall be treated as so agreed, subject
to any applicable requirements of Section 409A of the Code:
(a) Each option to acquire Shares (each, a “Company Stock Option”) under the Amended
and Restated 1999 Stock Option Plan (also known as the Amended and Restated 1999 Stock Plan) or the
2008 Incentive Compensation Plan (collectively, the “Equity Plans”), whether or not then
vested or exercisable, that is outstanding immediately prior to the Acceptance Time shall, as of
the Acceptance Time, become fully vested and be converted into the right to receive a payment in
cash, payable in U.S. dollars and without interest, equal to the product of (i) the excess, if any,
of (x) the Merger Consideration over (y) the exercise price per Share subject to such Company Stock
Option, multiplied by (ii) the number of Shares for which such Company Stock Option shall not
theretofore have been exercised. The Surviving Corporation shall pay the holders of Company Stock
Options the cash payments described in this Section 2.3(a), subject to the collection of the
applicable withholding taxes as set forth in Section 2.3(d), on or as soon as reasonably
practicable after the date on which the Effective Time occurs, but in any event within five (5)
Business Days thereafter.
(b) Each restricted stock unit award (a “RSU Award”) under the Equity Plans that is
outstanding immediately prior to the Effective Time shall be canceled at the Effective Time. In
exchange for each such canceled RSU Award, the holder shall be entitled to a lump sum cash
distribution payable by the Surviving Corporation in an amount determined by multiplying the number
of Shares subject to such canceled RSU Award, whether vested or unvested, by the Merger
Consideration (the “RSU Consideration”). The RSU Consideration for each cancelled RSU
Award shall be paid to the holder of that canceled award on or as soon as reasonably practicable
after the date on which the Effective Time occurs, but in any event within five (5) Business Days
thereafter, subject to the collection of applicable withholding taxes as provided in Section
2.3(d). However, to the extent any RSU Award is subject to a deferred payment schedule pursuant to
the applicable distribution provisions of Code Section 409A so that the RSU Consideration cannot be
paid to the holder within such five (5) Business-Day period without the holder’s incurrence of a
penalty tax and interest penalties under Code Section 409A, then the Surviving Corporation shall,
within five (5) Business Days following the Effective Time, deposit the RSU Consideration for each
such holder into a grantor trust that satisfies the requirements of Revenue Procedure 92-64 and
that will accordingly serve as the funding source for the Surviving Corporation to satisfy its
obligations to pay each such holder the held-back RSU Consideration to which such holder is
entitled, together with accrued interest thereon, as that consideration becomes payable in one or
more installments in accordance with
15
the deferred payment schedule applicable to that award. A separate account shall be booked
under such grantor trust for each holder entitled to such deferred RSU Consideration, and that
account shall be fully-vested at all times. However, the grantor trust shall at all time remain
subject to the claims of the general creditors of the Surviving Corporation, and each RSU Award
holder with an interest therein shall have only the rights of a general creditor with respect to
his or her portion of the deposited funds, which shall be maintained and located at all times in
the United States. Any interest, earnings or other proceeds earned in respect of the outstanding
balance of the trust fund as a result of the investment thereof by the trustee at the direction of
the Company or the trust fund beneficiaries, for the period commencing with the establishment of
such trust fund in accordance with this Section 2.3(b) and continuing through the date of the final
payment of that fund to the holders entitled to the deferred RSU Consideration, shall be for the
benefit of the beneficiaries of such trust fund, who shall be entitled to participate ratably in
such interest, earnings or other proceeds. The deferred RSU Consideration per cancelled RSU Award,
together with all accrued interest, earnings or other proceeds thereon through the actual payment
date, shall be distributed to the holder of that cancelled RSU Award upon the earliest to occur of
(i) each semi-annual date on which the Shares to which that RSU Consideration relates would have
been issued to the holder, pursuant to the issuance provisions in effect under that RSU Award, in
the absence of the Merger, (ii) the date such holder incurs a separation from service within the
meaning of Code Section 409A and the applicable Treasury Regulations thereunder, subject to any
required holdback under Code Section 409A if the holder is a “specified employee” for Code Section
409A purposes at the time of such separation from service, or (iii) the first date on which the
distribution can be made to such holder without contravention of any applicable provisions of Code
Section 409A, or as soon as administratively practicable following such applicable date, but in no
event later than five (5) Business Days after the occurrence of such applicable date. The holders
of the RSU Awards shall, as of the Effective Time, cease to have any further right or entitlement
to acquire Shares or any shares of the capital stock of Parent or the Surviving Corporation under
their canceled RSU Awards but shall at all times be fully-vested in their RSU Consideration,
together with any interest, earnings or other proceeds that accrues thereon while that
consideration may be deposited in the grantor trust in accordance herewith.
(c) Immediately prior to the Effective Time, the then-current offering period (as set forth in
the Company’s Amended and Restated 2004 Employee Stock Purchase Plan (the “ESPP”)) shall
terminate (the “Final Date”) and the payroll deductions of each participant accumulated as
of the Final Date for the then-current offering period shall be immediately applied to the purchase
of whole Shares in accordance with the terms of the ESPP, which number of Shares shall be canceled
and be converted in the Merger into the right to receive the Merger Consideration as provided in
Section 2.1(a) with respect to such Shares.
(d) The Surviving Corporation shall be entitled to deduct and withhold from the amounts
otherwise payable pursuant to this Section 2.3 to any holder of Company Stock Options or an RSU
Award such amounts as the Surviving Corporation is required to deduct and withhold with respect to
the making of such payment under the Code, or any provision of state, or local Tax Law, and the
Surviving Corporation shall make any required filings with and payments to Tax authorities relating
to any such deduction or withholding. To the extent that amounts are so deducted and withheld by
the Surviving Corporation, such withheld amounts shall be treated for all purposes of this
Agreement as having been paid to the holder of the
16
Company Stock Options or RSU Award in respect of which such deduction and withholding was made
by the Surviving Corporation.
(e) The Board of Directors (or the appropriate committee thereof) shall take such actions as
are necessary in connection with the foregoing provisions of this Section 2.3.
ARTICLE III
REPRESENTATIONS AND WARRANTIES OF THE COMPANY
REPRESENTATIONS AND WARRANTIES OF THE COMPANY
Except (i) as disclosed in, and reasonably apparent from, any report, schedule, form or other
document filed with, or furnished to, the SEC and publicly available prior to the date of this
Agreement (collectively, the “Filed SEC Documents”) or (ii) as disclosed in the disclosure
letter delivered by the Company to Parent immediately prior to the execution of this Agreement (the
“Company Disclosure Letter”, it being agreed that disclosure of any item in any section of
the Company Disclosure Letter shall also be deemed disclosure with respect to any other section of
this Agreement to which the relevance of such item is reasonably apparent), the Company represents
and warrants to Parent and the Purchaser as follows:
Section 3.1 Qualification, Organization, etc.
(a) Each of the Company and its Subsidiaries is a legal entity duly organized, validly
existing and in good standing under the Laws of its respective jurisdiction of organization, except
for such failures that would not, individually or in the aggregate, have a Company Material Adverse
Effect. Each of the Company and its Subsidiaries has all requisite corporate, partnership or
similar power and authority to own, lease and operate its properties and assets and to carry on its
business as presently conducted, except for such failures that would not, individually or in the
aggregate, have a Company Material Adverse Effect.
(b) Each of the Company and its Subsidiaries is duly qualified to do business and is in good
standing as a foreign corporation (or other legal entity) in each jurisdiction where the ownership,
leasing or operation of its assets or properties or conduct of its business requires such
qualification, except where the failure to be so qualified or in good standing would not,
individually or in the aggregate, have a Company Material Adverse Effect. The organizational or
governing documents of the Company and each of its Subsidiaries are in full force and effect and
neither the Company nor any Subsidiary is in violation of its organizational or governing
documents, in each case, except for such failures that would not, individually or in the aggregate,
have a Company Material Adverse Effect.
(c) As used in this Agreement, any reference to any fact, circumstance, event, change, effect
or occurrence having a “Company Material Adverse Effect” means any fact, circumstance,
event, change, effect or occurrence that, individually or in the aggregate with all other facts,
circumstances, events, changes, effects, or occurrences, has or would be reasonably expected to
have a material adverse effect on or with respect to the business, results of operation or
financial condition of the Company and its Subsidiaries, taken as a whole, provided, however, that,
Company Material Adverse Effect shall not include facts, circumstances, events, changes, effects or
occurrences (i) (A) generally affecting the pharmaceutical contract research organization industry
or the segments thereof in which the Company and its Subsidiaries operate
17
(except to the extent that such facts, circumstances, events, changes, effects or occurrences
materially and disproportionately have a greater adverse impact on the Company and its
Subsidiaries, taken as a whole, as compared to the adverse impact such facts, circumstances,
events, changes, effects or occurrences have on other Persons operating in the pharmaceutical
contract research organization industry or the segments thereof in which the Company and its
Subsidiaries operate; provided, that any such determination of whether a Company Material Adverse
Effect has occurred in connection with such changes shall be measured with respect to the Company
and its Subsidiaries, taken as a whole, after giving effect to the impact of such facts,
circumstances, events, changes, effects or occurrences at the level of impact generally experienced
by other companies operating in the pharmaceutical contract research organization industry or the
segments thereof in which the Company and its Subsidiaries operate), or (B) generally affecting the
economy or the financial, debt, credit or securities markets, in the United States, including
effects on the contract research organization industry or the segments thereof in which the Company
and its Subsidiaries operate, the economy or the financial, debt, credit or securities markets
resulting from any political conditions or developments in general, or resulting from any outbreak
or escalation of hostilities, declared or undeclared acts of war or terrorism (except to the extent
that such facts, circumstances, events, changes, effects or occurrences materially and
disproportionately have a greater adverse impact on the Company and its Subsidiaries, taken as a
whole, as compared to the adverse impact such facts, circumstances, events, changes, effects or
occurrences have on other Persons operating in the pharmaceutical contract research organization
industry or the segments thereof in which the Company and its Subsidiaries operate; provided, that
any such determination of whether a Company Material Adverse Effect has occurred in connection with
such changes shall be measured with respect to the Company and its Subsidiaries, taken as a whole,
after giving effect to the impact of such facts, circumstances, events, changes, effects or
occurrences at the level of impact generally experienced by other companies operating in the
pharmaceutical contract research organization industry or the segments thereof in which the Company
and its Subsidiaries operate); (ii) reflecting or resulting from changes or proposed changes in Law
(including rules and regulations), interpretations thereof, regulatory conditions or GAAP (or
authoritative interpretations thereof); (iii) resulting from actions of the Company or any of its
Subsidiaries which Parent has expressly requested or to which Parent has expressly consented, or
resulting from the announcement of the Offer, the Merger or the proposal thereof or this Agreement
and the transactions contemplated hereby, or from compliance by the Company with this Agreement;
(iv) resulting from changes in the share price or trading volume of the Company Common Stock or the
Company’s failure to meet any projections or forecasts or resulting from the Company’s results of
operations for the quarter ended December 31, 2008 or any subsequent quarter, including any
non-cash impairment charge for such period (but not the underlying causes of any such change in
share price or trading volume or failure to meet projections or forecasts, unless such causes are
otherwise excluded pursuant to other clauses of the proviso to this definition); (v) resulting from
the modification, delay or cancellation of contracts with clients of the Company or any of its
Subsidiaries, including those contracts included in the Company’s or any of its Subsidiaries
backlog, or the failure to generate new client contracts; or (vi) resulting from the Company’s
receipt of a going-concern opinion from its auditors based on a lack of a plan to repay the
Convertible Notes or if the Company is not Solvent as a result of the potential repayment of the
Convertible Notes.
18
Section
3.2 Capital Stock.
(a) The authorized capital stock of the Company consists of 40,000,000 shares of Company
Common Stock and 5,000,000 shares of Preferred Stock, par value $0.10 per share. As of February 2,
2009, (i) 19,797,146 shares of Company Common Stock were issued and outstanding, (ii) no shares of
Company Common Stock were held in treasury and (iii) (A) no shares of Company Common Stock were
reserved for issuance pursuant to the ESPP, (B) 3,100,000 shares of Company Common Stock were
reserved for issuance upon conversion of convertible senior notes of the Company and (C) 679,206
shares of Company Common Stock were reserved for issuance under the Equity Plans. All outstanding
Shares, and all shares of Company Common Stock reserved for issuance as noted in clause (iii) of
the foregoing sentence, when issued in accordance with the respective terms thereof, are or will be
duly authorized, validly issued, fully paid and non-assessable and free of pre-emptive or similar
rights. No Subsidiary of the Company owns any Shares. Section 3.2(a) of the Company Disclosure
Letter lists, as of the date hereof, each outstanding Company Stock Option and RSU, the number of
shares of Company Common Stock payable thereunder or to which such award relates and the exercise
price thereof.
(b) Except as set forth in Section 3.2(a) above or in Section 3.2(b) of the Company Disclosure
Letter, as of the date hereof, (i) the Company does not have any shares of its capital stock issued
or outstanding and (ii) there are no outstanding subscriptions, options, warrants, calls,
convertible securities, stock-based performance units or other similar rights, agreements or
commitments relating to the issuance of capital stock or other equity interests to which the
Company or any of its Subsidiaries is a party obligating the Company or any of its Subsidiaries to
(A) issue, transfer or sell any shares of capital stock or other equity interests of the Company or
any of its Subsidiaries or securities convertible into or exchangeable for such shares or equity
interests, (B) issue, grant, extend or enter into any such subscription, option, warrant, call,
convertible securities or other similar right, agreement or commitment, (C) redeem or otherwise
acquire any such shares of capital stock or other equity interests or (D) provide a material amount
of funds to, or make any material investment (in the form of a loan, capital contribution or
otherwise) in, the Company or any Subsidiary of the Company.
(c) Except as set forth in Section 3.2(a) or Section 3.2(b) above, neither the Company nor any
of its Subsidiaries has outstanding bonds, debentures, notes or other obligations, the holders of
which have the right to vote (or which are convertible into or exercisable for securities having
the right to vote) with the stockholders of the Company on any matter.
(d) There are no stockholder agreements, voting trusts or other agreements or understandings
to which the Company or any of its Subsidiaries is a party with respect to the voting,
registration, redemption, repurchase or disposition of the capital stock or other equity interest
of the Company or any of its Subsidiaries.
Section
3.3 Subsidiaries. Section 3.3 of the Company Disclosure Letter sets forth a complete and
correct list of each “significant subsidiary” of the Company as such term is defined in Regulation
S-X promulgated by the SEC (each, a “Significant Subsidiary”). Section 3.3 of the Company
Disclosure Letter also sets forth the jurisdiction of organization and percentage of
19
outstanding equity interests (including partnership interests and limited liability company
interests) owned by the Company or its Subsidiaries of each Significant Subsidiary. All equity
interests (including partnership interests and limited liability company interests) of the
Company’s Subsidiaries are owned by the Company or by a Subsidiary of the Company, and all such
equity interests have been duly and validly authorized and are validly issued, fully paid and
non-assessable and were not issued in violation of any preemptive or similar rights, purchase
option, call or right of first refusal or similar rights. All such equity interests owned by the
Company or any of its Subsidiaries are free and clear of any Liens, other than restrictions on
transfer imposed by applicable Law. Except for its interests in Subsidiaries of the Company, or as
disclosed in Section 3.3 of the Company Disclosure Letter, the Company does not own, directly or
indirectly, 5% or more of the outstanding capital stock of, or other equity interests in, any
Person, or any options, warrants, rights or securities convertible, exchangeable or exercisable
therefor.
Section
3.4 Corporate Authority Relative to This Agreement; No Violation.
(a) The Company has the requisite corporate power and authority to enter into and perform its
obligations under this Agreement and, in the case of the Merger, subject to receipt of the Company
Stockholder Approval, to consummate the transactions contemplated hereby. The execution, delivery
and performance of this Agreement and the consummation of the transactions contemplated hereby have
been duly and validly authorized by the Board of Directors and, except, in the case of the Merger,
for (i) the Company Stockholder Approval and (ii) the filing of the Certificate of Merger with the
Secretary of State of the State of Delaware, no other corporate proceedings on the part of the
Company are necessary to authorize the consummation of the transactions contemplated hereby.
Subject to Section 5.2(d), the Board of Directors has, by resolutions duly adopted at a meeting
duly called and held, (x) duly and validly approved and declared advisable this Agreement and the
transactions contemplated hereby, (y) determined that the transactions contemplated by this
Agreement are advisable and in the best interests of the Company and its stockholders and (z)
resolved to make the Recommendation. This Agreement has been duly and validly executed and
delivered by the Company and, assuming this Agreement constitutes the valid and binding agreement
of Parent and the Purchaser, constitutes the valid and binding agreement of the Company,
enforceable against the Company in accordance with its terms, subject to the effects of bankruptcy,
insolvency, fraudulent conveyance, reorganization, moratorium and other similar Laws relating to or
affecting creditors’ rights generally, general equitable principles (whether considered in a
proceeding in equity or at Law) and any implied covenant of good faith and fair dealing.
(b) Other than in connection with or in compliance with (i) the DGCL, (ii) the Exchange Act,
(iii) the Xxxx-Xxxxx-Xxxxxx Antitrust Improvements Act of 1976, as amended, and the rules and
regulations promulgated thereunder (the “HSR Act”), or any applicable Other Antitrust Law,
and (iv) the approvals set forth on Section 3.4(b) of the Company Disclosure Letter (clauses (i)
through (iv), collectively, the “Company Approvals”), no material authorization, consent,
approval or order of, or filing with, or notice to, any United States or foreign governmental or
regulatory agency, commission, court, body, entity or authority (each, a “Governmental
Entity”) is necessary, under applicable Law, in connection with the execution, delivery and
performance of this Agreement by the Company or the consummation by the Company of the transactions
contemplated hereby.
20
(c) Except as set forth in Section 3.4(c) of the Company Disclosure Schedule, the execution,
delivery and performance by the Company of this Agreement does not, and the consummation of the
transactions contemplated hereby and compliance with the provisions hereof by the Company will not,
(i) result in any breach or violation of, or default (with or without notice or lapse of time, or
both) under, require consent under, or give rise to a right of termination, cancellation,
modification or acceleration of any obligation or to the loss of any benefit under any loan,
guarantee of indebtedness or credit agreement, note, bond, mortgage, indenture, lease, agreement,
contract, purchase or sale order, instrument, permit, concession, franchise, right or license
binding upon the Company or any of its Subsidiaries or result in the creation of any liens, claims,
mortgages, encumbrances, pledges, security interests, equities or charges of any kind (each, a
“Lien”) upon any of the properties, assets or rights of the Company or any of its
Subsidiaries, (ii) conflict with or result in any violation of any provision of the certificate or
articles of incorporation or by-laws or other equivalent organizational document of the Company or
any of its Subsidiaries or (iii) assuming that all Company Approvals are duly obtained, conflict
with or violate any applicable Laws, other than, in the case of clauses (i), (ii) (to the extent
relating to Subsidiaries) and (iii), as would not, individually or in the aggregate, have a Company
Material Adverse Effect and other than as may arise in connection with facts and circumstances
particular to Parent and its Affiliates.
Section
3.5 Reports and Financial Statements.
(a) The Company and its Subsidiaries have timely filed all forms, documents, statements,
reports and other materials, together with any amendments required to be made thereto, required to
be filed by them with the SEC since January 1, 2007 (the forms, documents, statements, reports and
other materials, together with any amendments required to be made thereto, filed with the SEC since
January 1, 2007, including any amendments thereto, the “Company SEC Documents”). As of
their respective dates, the Company SEC Documents complied, and each of the Company SEC Documents
filed subsequent to the date of this Agreement will comply, in all material respects with the
requirements of the Securities Act of 1933, as amended (the “Securities Act”), the Exchange
Act and the Xxxxxxxx-Xxxxx Act of 2002 (the “Xxxxxxxx-Xxxxx Act”), as the case may be, and
the applicable rules and regulations promulgated thereunder. As of the time of filing with the
SEC, none of the Company SEC Documents so filed or that will be filed subsequent to the date of
this Agreement contained or will contain, as the case may be, any untrue statement of a material
fact or omitted or will omit to state any material fact required to be stated therein or necessary
in order to make the statements therein, in the light of the circumstances under which they were or
will be made, not misleading. No Subsidiary of the Company is subject to the periodic reporting
requirements of the Exchange Act.
(b) The financial statements (including all related notes and schedules) of the Company and
its Subsidiaries included in the Company SEC Documents complied as to form in all material respects
with the published rules and regulations of the SEC with respect thereto, fairly present in all
material respects the financial position of the Company and its Subsidiaries, as at the respective
dates thereof, and the results of their operations and their cash flows for the respective periods
then ended (subject, in the case of the unaudited statements, to normal year-end audit adjustments
and to any other adjustments expressly described therein, including the notes thereto, none of
which are expected to be material) and were prepared in conformity with
21
United States generally accepted accounting principles (“GAAP”) (except, in the case
of the unaudited statements, as permitted by the SEC) applied on a consistent basis during the
periods involved (except as may be expressly indicated therein or in the notes thereto).
(c) The Company and its Subsidiaries have established and maintain “disclosure controls and
procedures” (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). The
Company’s and its Subsidiaries’ disclosure controls and procedures are designed to reasonably
ensure that information required to be disclosed in the Company’s periodic reports filed or
submitted under the Exchange Act is recorded, processed, summarized and reported within the time
periods specified in the rules and forms of the SEC, and that all material information is
accumulated and communicated to the Company’s management as appropriate to allow timely decisions
regarding required disclosure and to make the certifications required pursuant to Sections 302 of
the Xxxxxxxx-Xxxxx Act of 2002.
Section
3.6 No Undisclosed Liabilities. Except (i) as reflected or reserved against in the
Company’s consolidated balance sheet as of September 30, 2008 (or the notes thereto) included in
the Company SEC Documents filed prior to the date hereof, (ii) for liabilities or obligations
incurred in connection with the transactions contemplated by this Agreement, (iii) for liabilities
and obligations incurred in the ordinary course of business consistent with past practice since
September 30, 2008 and (iv) as set forth in Section 3.6 of the Company Disclosure Letter, neither
the Company nor any Subsidiary of the Company has any liabilities or obligations of any nature that
would be required in accordance with GAAP to be set forth on the Company’s consolidated balance
sheet, whether or not accrued, contingent or otherwise and whether due or to become due, that
would, individually or in the aggregate, have a Company Material Adverse Effect.
Section
3.7 Compliance with Law; Permits. Since January 1, 2007, the businesses of each of the
Company and its Subsidiaries have been conducted in compliance, in all material respects, with all
federal, state, local or foreign laws, statutes, ordinances, rules, regulations, Orders,
arbitration awards, agency requirements, licenses and permits of each Governmental Entity
(collectively, “Laws”), except for such violations that would not, individually or in the
aggregate, have a Company Material Adverse Effect. The Company and its Subsidiaries have all
material permits, licenses, franchises, variances, exemptions, Orders, authorizations, consents and
approvals issued or granted by a Governmental Entity necessary to conduct their business as
presently conducted, except those the absence of which would not, individually or in the aggregate,
have a Company Material Adverse Effect (collectively, the “Permits”). Neither the Company
nor any Subsidiary has received notice from any Governmental Authority (i) asserting a material
violation of any Law, (ii) threatening revocation or non-renewal of any Permit material to the
business of the Company and its Subsidiaries, or (iii) restricting or limiting in any material
respect the operations of the Company and its Subsidiaries as currently conducted or purposed to be
conducted.
Section
3.8 Environmental Laws and Regulations.
(a) Except as would not, individually or in the aggregate, have a Company Material Adverse
Effect, (i) the Company and each of its Subsidiaries have conducted their respective businesses in
compliance with all, and have not violated any, applicable
22
Environmental Laws, (ii) there has been no release of any Hazardous Substance in any manner
that could reasonably be expected to give rise to any remedial obligation, corrective action
requirement or liability of or against the Company, any of its Subsidiaries or any other Person
whose liability for such matters the Company or any of its Subsidiaries is responsible for by Law
or Contract, under applicable Environmental Laws, (iii) neither the Company nor any of its
Subsidiaries has received in writing any claims, notices, demand letters or requests for
information (except for such claims, notices, demand letters or requests for information the
subject matter of which has been resolved prior to the date of this Agreement) from any
Governmental Entity or any other Person asserting that the Company or any of its Subsidiaries is in
violation of, or liable under, any Environmental Law, (iv) no Hazardous Substance has been disposed
of, arranged to be disposed of, released or transported in violation of any applicable
Environmental Law, or in a manner giving rise to, or that would reasonably be expected to give rise
to, any liability under Environmental Law, from any current or former properties or facilities
while owned or operated by the Company or any of its Subsidiaries or as a result of, or in
connection with, any operations or activities of the Company, any of its Subsidiaries, any other
Person whose liability for such matters the Company is responsible for by Law or Contract, at any
location and Hazardous Substances are not otherwise present at or about any such properties or
facilities in amount or condition that would reasonably be expected to result in liability to the
Company or any of its Subsidiaries any other Person whose liability for such matters the Company is
responsible for by Law or Contract under Environmental Law, (v) neither the Company, its
Subsidiaries nor any of their respective properties or facilities are subject to, or are threatened
to become subject to, any liabilities relating to any suit, settlement, court order, administrative
order, regulatory requirement, judgment or written claim asserted or arising under any
Environmental Law or any agreement relating to environmental liabilities, (vi) neither the Company
nor any of its Subsidiaries has assumed, undertaken, provided an indemnity with respect to, become
contractually responsible for, or have otherwise become subject to any liability of any other
Person arising under any Environmental Law, and (vii) the Company has provided Parent with complete
copies of any and all environmental assessment or audit reports or other similar studies or
analyses generated within the last two years and in the Company’s or any Subsidiary’s possession
that relate to the assets or properties of the Company or any Subsidiary.
(b) As used herein, “Environmental Law” means any Law relating to (i) the protection,
preservation, pollution or restoration of the environment (including air, surface water,
groundwater, drinking water supply, surface land, subsurface land, plant and animal life or any
other natural resource) or protection of human health, or (ii) the exposure to, or the use,
storage, recycling, treatment, generation, transportation, processing, handling, labeling,
production, release or disposal of Hazardous Substances.
(c) As used herein, “Hazardous Substance” means any substance listed, defined,
designated, classified or regulated as a waste, pollutant or contaminant or as hazardous, toxic,
radioactive or dangerous or any other term of similar import under any Environmental Law, including
all Hazardous Substances, Oils, Pollutants or Contaminants in the National Oil and Hazardous
Substances Pollution Contingency Plan, 40 C.F.R. § 300.5, toxic mold and petroleum.
23
Section
3.9 Employee Benefit Plans.
(a) Section 3.9(a) of the Company Disclosure Letter sets forth a true and complete list of
each material Company Benefit Plan. For purposes of this Agreement, the term “Company Benefit
Plan” shall mean any employee or non-employee director benefit plan, arrangement or agreement,
including, without limitation, any such plan that is an employee welfare benefit plan within the
meaning of Section 3(1) of the Employee Retirement Income Security Act of 1974, as amended
(“ERISA”), an employee pension benefit plan within the meaning of Section 3(2) of ERISA
(whether or not such plan is subject to ERISA), it being agreed that any such employee pension
benefit plan is “material” for purposes of this Agreement, or a bonus, incentive, deferred
compensation, vacation, stock purchase, stock option, severance, employment, change of control or
fringe benefit plan, program or agreement that is sponsored or maintained by the Company or any of
its Subsidiaries to or for the benefit of the current or former employees, independent contractors
or non-employee directors of the Company and its Subsidiaries.
(b) The Company has heretofore made available to Parent true and complete copies of each of
the material Company Benefit Plans and (i) each writing constituting a part of such Company Benefit
Plan, including all amendments thereto; (ii) the two most recent (A) Annual Reports (Form 5500
Series) and accompanying schedules, if any, (B) audited financial statements and (C) actuarial
valuation reports; (iii) the most recent determination letter from the Internal Revenue Service
(“IRS”) (if applicable) for such Company Benefit Plan; and (iv) any related trust agreement
or funding instrument now in effect or required in the future as a result of the transactions
contemplated by this Agreement.
(c) Except as would not, individually or in the aggregate, have a Company Material Adverse
Effect: (i) each of the Company Benefit Plans has been established, operated and administered in
all material respects with applicable Laws, including, but not limited to, ERISA, the Code, the
Laws of the relevant non-U.S. jurisdiction and in each case the regulations thereunder; (ii) each
of the Company Benefit Plans intended to be “qualified” within the meaning of Section 401(a) of the
Code has received a favorable determination letter from the IRS, and there are no existing
circumstances or events that have occurred that would reasonably be expected to result in the
revocation of such letter; (iii) no Company Benefit Plan is or has during the last six years been
subject to Title IV of ERISA; (iv) no Company Benefit Plan provides health, life insurance or
disability benefits (whether or not insured), with respect to current or former employees or
directors of the Company or its Subsidiaries beyond their retirement or other termination of
service, other than (A) coverage mandated by applicable Law, (B) death benefits or retirement
benefits under any “employee pension plan” (as such term is defined in Section 3(2) of ERISA) or
(C) as required pursuant to the express terms of existing contracts between the Company and its
employees that will remain in effect following the Effective Time; (v) no liability under Title IV
of ERISA has been incurred by the Company, its Subsidiaries or any ERISA Affiliate of the Company
that has not been satisfied in full, and no condition exists that presents a risk to the Company,
its Subsidiaries or any ERISA Affiliate of the Company of incurring a liability thereunder; (vi) no
Company Benefit Plan is a “multiemployer pension plan” (as such term is defined in Section 3(37) of
ERISA) or a plan that has two or more contributing sponsors at least two of whom are not under
common control, within the meaning of Section 4063 of ERISA; (vii) all contributions or other
amounts payable by the Company or its
24
Subsidiaries as of the date hereof with respect to each Company Benefit Plan in respect of
current or prior plan years have been paid or accrued in accordance with GAAP; (viii) neither the
Company nor its Subsidiaries has engaged in a transaction in connection with which the Company or
its Subsidiaries would reasonably be expected to be subject to either a civil penalty assessed
pursuant to Section 409 or 502(i) of ERISA or a Tax imposed pursuant to Section 4975 or 4976 of the
Code; (ix) with respect to each Company Benefit Plan that is not subject to United States Law (a
“Foreign Company Benefit Plan”) (A) the fair market value of the assets of each funded
Foreign Company Benefit Plan, the liability of each insurer for any Company Foreign Benefit Plan
funded through insurance or the book reserve established for any Foreign Benefit Plan, together
with any accrued contributions, is sufficient to procure or provide for the accrued benefit
obligations, as of the Closing Date, with respect to all current and former participants in such
plan according to the actuarial assumptions and valuations most recently used to determine employer
contributions to such Foreign Benefit Plan and no transaction contemplated by this Agreement shall
cause such assets or insurance obligations to be less than such benefit obligations and (B) each
Foreign Company Benefit Plan required to be registered has been registered and has been maintained
in good standing with applicable regulatory authorities; and (x) there are no pending, threatened
or anticipated claims (other than routine claims for benefits) by, on behalf of or against any of
the Company Benefit Plans or any trusts related thereto which would reasonably be expected to
result in any material liability of the Company or any of its Subsidiaries. “ERISA
Affiliate” means, with respect to any entity, trade or business, any other entity, trade or
business that is a member of a group described in Section 414(b), (c), (m) or (o) of the Code or
Section 4001(b)(1) of ERISA that includes the first entity, trade or business, or that is a member
of the same “controlled group” as the first entity, trade or business pursuant to Section
4001(a)(14) of ERISA.
(d) Each Company Benefit Plan or portion thereof that is a “non-qualified deferred
compensation plan” within the meaning of Section 409A(d)(1) of the Code (a “409A Plan”)
complies in all material respects with the requirements of Section 409A of the Code and the
guidance promulgated thereunder, no payment to be made under any 409A Plan is or will be subject to
the interest and additional tax payable pursuant to Section 409A(a)(1)(B) of the Code, except as
would not, individually or in the aggregate, have a Company Material Adverse Effect, and neither
the Company nor any Subsidiary is party to, or otherwise obligated under, any contract, agreement,
plan or arrangement that provides for the gross-up of taxes imposed by Section 409A(a)(1)(B) of the
Code.
(e) Each Company Stock Option (i) was granted in compliance with all applicable Laws and all
of the terms and conditions of the relevant plan pursuant to which it was issued, (ii) has an
exercise price per share of Company Common Stock equal to or greater than the fair market value of
a share of Company Common Stock on the date of such grant, and (iii) has a grant date identical to
the date on which the Board of Directors or compensation committee actually awarded such stock
option.
(f) Except as set forth in Section 3.9(f) of the Company Disclosure Letter, no Company Benefit
Plan exists that as a result of the consummation of the transactions contemplated by this Agreement
will, either alone or in combination with another event, (i) entitle any employee or officer of the
Company or any of its Subsidiaries to severance pay, unemployment compensation or any other
payment, except as expressly provided in this
25
Agreement or as required by applicable Law, (ii) accelerate the time of payment or vesting, or
increase the amount of compensation due any such employee, consultant or officer, or (iii) result
in payments under any of the Company Benefit Plans which would not be deductible under Section 280G
of the Code. Except for the Company Stock Options and RSUs listed in Section 3.2(a) of the Company
Disclosure Letter, there is no stock option, restricted stock unit, or other award or right
outstanding under the Equity Plans or the Company’s Amended and Restated 2004 Employee Stock
Purchase Plan or any other equity compensation plan maintained by the Company or any of its
Subsidiaries that will become vested and/or exercisable as a result solely of the transactions
contemplated by this Agreement.
Section
3.10 Interested Party Transactions. Except for employment-related Contracts filed or
incorporated by reference as an exhibit to a Filed SEC Document or Company Benefit Plans, Section
3.10 of the Company Disclosure Letter sets forth a correct and complete list of the contracts or
arrangements that are in existence as of the date of this Agreement under which the Company has any
existing or future material liabilities between the Company or any of its Subsidiaries, on the one
hand, and, on the other hand, any (A) present executive officer (as defined pursuant to Section 16
of the Exchange Act) or director of either the Company or any of its Subsidiaries or any person
that has served as such an executive officer (as defined pursuant to Section 16 of the Exchange
Act) or director within the last two (2) years or any of such officer’s or director’s immediate
family members or any Affiliate of any such officer, director or any immediate family member of any
such officer or director (B) record or beneficial owner of more than 5% of the Shares as of the
date hereof or any of such owner’s immediate family members or any Affiliate of any such owner or
any such owner’s immediate family members (each, an “Affiliate Transaction”).
Section
3.11 Absence of Certain Changes or Events. Except as disclosed in Section 3.11 of the
Company Disclosure Letter, since September 30, 2008 through the date of this Agreement: (a) except
for the transactions contemplated hereby, the business of the Company and its Subsidiaries has been
conducted, in all material respects, in the ordinary course of business; and (b) there have not
been any facts, circumstances, events, changes, effects or occurrences that, individually or in the
aggregate, have had or would reasonably be expected to have a Company Material Adverse Effect.
Section
3.12 Litigation. Except as set forth in Section 3.12 of the Company Disclosure Letter,
there are no (i) actions, suits, proceedings, arbitrations or claims, (“Actions”) pending
or, to the Knowledge of the Company, threatened or, to the Knowledge of the Company,
investigations, against or affecting the Company or any of its Subsidiaries, or any of their
respective properties or assets, at Law or in equity, or (ii) material Orders against the Company
or any of its Subsidiaries, which would, in the case of clause (i), individually or in the
aggregate, have a Company Material Adverse Effect.
Section
3.13 Offer Documents; Schedule 14D-9; Proxy Statement.
(a) None of the information supplied or to be supplied by the Company for inclusion or
incorporation by reference in the Offer Documents will, when filed with the SEC, when distributed
or disseminated to the Company’s stockholders, and at the Expiration Date, contain any untrue
statement of a material fact or omit to state any material fact required to be
26
stated therein or necessary in order to make the statements made therein, in the light of the
circumstances under which they were made, not misleading. The Schedule 14D-9 will comply as to
form in all material respects with the provisions of Rule 14d-9 of the Exchange Act and any other
applicable federal securities laws and will not, when filed with the SEC, when distributed or
disseminated to the Company’s stockholders, and at the Expiration Date, contain any untrue
statement of a material fact or omit to state any material fact required to be stated therein or
necessary in order to make the statements made therein, in light of the circumstances under which
they were made, not misleading; provided that no representation is made by the Company with respect
to information supplied by or related to, or the sufficiency of disclosure related to, Parent, the
Purchaser or any Affiliate of Parent or the Purchaser.
(b) The Proxy Statement, if any, will not at the time of the mailing of the Proxy Statement to
the stockholders of the Company, at the time of the Company Meeting, and at the time of any
amendments thereof or supplements thereto, contain any untrue statement of a material fact or omit
to state any material fact required to be stated therein or necessary in order to make the
statements therein, in light of the circumstances under which they were made, not misleading;
provided that no representation is made by the Company with respect to information supplied by or
related to, or the sufficiency of disclosures related to, Parent, the Purchaser or any Affiliate of
Parent or the Purchaser. The Proxy Statement, if any, will comply as to form in all material
respects with the requirements of the Exchange Act.
Section
3.14 Tax Matters.
(a) Except as would not, individually or in the aggregate, have a Company Material Adverse
Effect, (i) the Company and each of its Subsidiaries have prepared and timely filed (taking into
account any valid extension of time within which to file) all Tax Returns required to be filed by
any of them and all such Tax Returns are complete and accurate, (ii) the Company and each of its
Subsidiaries have timely paid all Taxes that are required to be paid by any of them (whether or not
shown on any Tax Return), except with respect to matters contested in good faith through
appropriate proceedings and for which adequate reserves have been established on the financial
statements of the Company and its Subsidiaries in accordance with GAAP, (iii) the Company has made
adequate provision in accordance with GAAP in the financial statements included in the Company SEC
Documents for all Taxes of the Company and each of its Subsidiaries not yet due and payable as of
the date of such financial statements, (iv) the U.S. consolidated federal income Tax Returns of the
Company through the Tax year ending December 31, 2003 have been examined (or the period for
assessment of the Taxes in respect of which such Tax Return were required to be filed has expired)
and the U.S. consolidated federal income Tax Returns of the Company for the Tax years ending
December 31, 2004 are as of the date hereof being examined by the IRS, (v) except as disclosed in
writing to the Purchaser, there are no outstanding waivers of statutes of limitations that have
been given with respect to any Taxes of the Company or any of its Subsidiaries, (vi) all
assessments for Taxes due with respect to completed and settled examinations or any concluded
litigation have been fully paid, (vii) except as disclosed in writing to the Purchaser, there are
no audits, examinations, investigations or other proceedings pending or, to the Knowledge of the
Company, threatened in writing in respect of Taxes or Tax matters of the Company or any of its
Subsidiaries, (viii) there are no Liens for Taxes on any of the assets of the Company or any of its
Subsidiaries other than statutory Liens for Taxes not yet due and payable or Liens for Taxes that
are being contested in
27
good faith through appropriate proceedings and for which adequate reserves have been
established on the financial statements of the Company and its Subsidiaries in accordance with
GAAP, (ix) neither the Company nor any of its Subsidiaries is a party to any agreement or
arrangement relating to the apportionment, sharing, assignment or allocation of any Tax or Tax
asset (other than an agreement or arrangement solely among members of a group the common parent of
which is the Company or a Subsidiary of the Company) or has any liability for Taxes of any Person
(other than the Company or any of its Subsidiaries) under Treasury Regulation Section 1.1502-6 (or
any analogous or similar provision of state, local or foreign Tax Law), (x) neither the Company nor
any of its Subsidiaries is or has been a “United States real property holding corporation” (as
defined in Section 897(c)(2) of the Code) during the applicable period specified in Section
897(c)(1)(A)(ii) of the Code, (xi) neither the Company nor any of its Subsidiaries has been a
“distributing corporation” or a “controlled corporation” (within the meaning of Section
355(a)(1)(A) of the Code) in a distribution of stock to which Section 355 of Code (or so much of
Section 356 of the Code as relates to Section 355 of the Code) applies and which occurred within
two years of the date of this Agreement, and (xii) none of the Company or any of its Subsidiaries
has been a party to any “listed transaction” within the meaning of Treasury Regulation
1.6011-4(b)(2).
(b) As used in this Agreement, (i) “Taxes” means any and all federal, state, local or
foreign taxes, imposts, levies or other like assessments, including all net income, gross receipts,
capital, sales, use, ad valorem, value added, transfer, franchise, profits, inventory, capital
stock, license, withholding, payroll, employment, social security, unemployment, excise, severance,
stamp, occupation, property and estimated taxes, customs duties, and other taxes of any kind
whatsoever, including any and all interest, penalties, additions to tax or additional amounts
imposed by any Governmental Entity in connection with respect thereto, and (ii) “Tax
Return” means any return, report or similar filing (including any attached schedules,
supplements and additional or supporting material) filed or required to be filed with respect to
Taxes, including any information return, claim for refund, amended return or declaration of
estimated Taxes (and including any amendments with respect thereto).
Section
3.15 Labor Matters; Employment Agreements.
(a) Neither the Company nor any of its Subsidiaries is a party to, or bound by, any collective
bargaining agreement, contract or other agreement or understanding with a labor union or labor
organization. Neither the Company nor any of its Subsidiaries is subject to any pending or, to the
Knowledge of the Company, threatened material dispute, strike, work stoppage, walkout, slowdown or
lockout, and no such material dispute, strike, work stoppage, walkout, slowdown or lockout has
occurred since January 1, 2007. To the Knowledge of the Company, there are no organizational
efforts with respect to the formation of a collective bargaining unit presently being made or
threatened involving employees of the Company or any of its Subsidiaries, and no such
organizational activity has occurred since January 1, 2007. There are no complaints or lawsuits
pending, or to the Knowledge of the Company, threatened against the Company or any of its
Subsidiaries brought by or on behalf of any current or former employee of the Company of the
Company or any of its Subsidiaries, except as would not, individually or in the aggregate, have a
Company Material Adverse Effect.
28
(b) Section 3.15(b) of the Company Disclosure Letter sets forth a true and complete list of
each employment, retention, severance, consulting, change of control or similar agreement currently
in effect between the Company and an officer or an employee of the Company or any Subsidiary
(“Company Employment Agreement”). (i) Each Company Employment Agreement is valid and
binding on the Company and any of its Subsidiaries to the extent it is a party thereto, as
applicable, and, as of the date hereof, to the Knowledge of the Company, each other party thereto,
and is in full force and effect and enforceable in accordance with its terms, (ii) the Company and
each of its Subsidiaries, and, as of the date hereof, to the Knowledge of the Company, any other
party thereto, is in material compliance with, and has performed in all material respects all
obligations required to be performed by it under, each Company Employment Agreement, (iii) neither
the Company nor any of its Subsidiaries has received written notice of the existence of any event
or condition which constitutes, or, after notice or lapse of time or both, will constitute, a
default on the part of the Company or any of its Subsidiaries under any such Company Employment
Agreement, and (iv) except as disclosed in Section 3.15(b) of the Company Disclosure Letter, no
event, condition or circumstance has occurred or existed, or will occur or exist as a result of the
transactions, that would permit any officer or employee of the Company who has entered into a
Company Employment Agreement to terminate his or her employment by “Resignation for Good Reason”
(as defined in each Company Employment Agreement) or similar concept.
Section
3.16 Intellectual Property. Except as would not, individually or in the aggregate, have a
Company Material Adverse Effect, either the Company or a Subsidiary of the Company owns, or is
licensed or otherwise possesses adequate rights to use, all trademarks, trade names, service marks,
service names, xxxx registrations, logos, assumed names, domain names, registered and unregistered
copyrights, software, patents or other intellectual property, and all applications and
registrations used in their respective businesses as currently conducted (collectively, the
“Intellectual Property”). Except as would not, individually or in the aggregate, have a
Company Material Adverse Effect or as set forth in Section 3.16 of the Company Disclosure Letter,
(i) there are no pending or, to the Knowledge of the Company, threatened in writing claims by any
Person alleging infringement by the Company or any of its Subsidiaries for their use of the
Intellectual Property of the Company or any of its Subsidiaries, (ii) to the Knowledge of the
Company, the conduct of the business of the Company and its Subsidiaries does not infringe any
Intellectual Property rights of any Person, (iii) neither the Company nor any of its Subsidiaries
has made any claim of a violation or infringement by others of its rights to or in connection with
the Intellectual Property of the Company or any of its Subsidiaries and (iv) to the Knowledge of
the Company, no Person is infringing any Intellectual Property of the Company or any of its
Subsidiaries.
Section
3.17 Property.
(a) Section 3.17(a) of the Company Disclosure Letter lists the real property owned in fee or
leased by the Company or any of its Subsidiaries. Such owned real property and leased real
property constitutes all of the real property used or held for use in the business of the Company
and its Subsidiaries.
(b) Except as would not, individually or in the aggregate, have a Company Material Adverse
Effect, the Company or a Subsidiary of the Company owns and has good and
29
valid title to all of its owned real property and good title to all its owned personal
property and has valid and subsisting leasehold interests in all of its leased properties,
sufficient to conduct their respective businesses as currently conducted, free and clear of all
Liens (except in the case of real property for title exceptions, defects, encumbrances, liens,
charges, restrictions, restrictive covenants and other matters, whether or not of record, which in
the aggregate do not materially affect the continued use of the property for the purposes for which
the property is currently being used). All leases under which the Company or any of its
Subsidiaries lease any real or personal property are valid and in full force and effect against the
Company or any of its Subsidiaries and, as of the date hereof, to the Company’s Knowledge, the
counterparties thereto, in accordance with their respective terms, and there is not, under any of
such leases, any existing default by the Company or any of its Subsidiaries which, with notice or
lapse of time or both, would become a default by the Company or any of its Subsidiaries.
(c) Except as would not, individually or in the aggregate, have a Company Material Adverse
Effect, all structures, buildings and other improvements on the real property owned or leased by
the Company or any of its Subsidiaries, including, without limitation, (i) the roof, roof membrane,
roof covering, floor, foundation, slab, load bearing walls and other structural elements thereof,
and (ii) all heating, ventilating, air conditioning, mechanical, electrical and plumbing systems
therein are in good operating order and condition, without material deferred maintenance, and, to
the Company’s Knowledge, have been and are being regularly and properly maintained in accordance
with all applicable manufacturers’ and service warranties in all respects. There are no (A)
pending or, to the Company’s Knowledge, threatened actions in eminent domain or (B) condemnations
with respect to any such real property or the structures, buildings or other improvements thereon
or any portion thereof.
Section
3.18 Required Vote of the Company Stockholders. The affirmative vote of the holders of
outstanding shares of Company Common Stock, voting together as a single class, representing at
least a majority of all the votes then entitled to be cast at a meeting of stockholders, is the
only vote of holders of any class of securities of the Company which is required to approve and
adopt this Agreement and the Merger and the other transactions contemplated hereby (the
“Company Stockholder Approval”).
Section
3.19 Material Contracts.
(a) The Company has made available to Parent true, correct and complete copies of (including
all amendments or modifications to), as of the date of this Agreement, all Contracts to which the
Company or any of its Subsidiaries is a party or by which the Company, any of its Subsidiaries or
any of their respective properties or assets is bound that:
(i) are or would be required to be filed by the Company as a “material contract” pursuant to
Item 601(b)(10) of Regulation S-K under the Securities Act or disclosed by the Company on a Current
Report on Form 8-K;
(ii) relate to the formation, creation, operation, management or control of any partnership or
joint venture that is material to the business of the Company and its Subsidiaries, taken as a
whole;
30
(iii) relate to indebtedness for borrowed money having an outstanding principal amount or
payment obligation (contingent or otherwise) in excess of five hundred thousand dollars ($500,000);
(iv) were entered into after December 31, 2007 or have not yet been consummated and involve
the acquisition from another Person or disposition to another Person, directly or indirectly (by
merger or otherwise), of assets or capital stock or other equity interests of another Person for
aggregate consideration under such Contract (or series of related Contracts) in excess of one
hundred twenty-five thousand dollars ($125,000) (other than acquisitions or dispositions of
inventory in the ordinary course of business; capital expenditures and capital commitments (which
are covered in clause (vi)); and dispositions of cash in connection with the repayment of
Indebtedness at the maturity thereof);
(v) relate to an acquisition, divestiture, merger or similar transaction that contains
representations, covenants, indemnities or other obligations (including indemnification, “earn-out”
or other contingent obligations), that are still in effect and would reasonably be expected to
result in payments in excess of two hundred fifty thousand dollars ($250,000) individually;
(vi) other than an acquisition subject to clause (v) above, an acquisition in the ordinary
course of business, consistent with past practice, or an acquisition of inventory under five
hundred thousand dollars ($500,000) individually, obligate the Company to make any capital
commitment or capital expenditure;
(vii) are license agreements that are material to the business of the Company and its
Subsidiaries, taken as a whole, pursuant to which the Company or any of its Subsidiaries is a party
and licenses in Intellectual Property or licenses out Intellectual Property owned by the Company or
its Subsidiaries, other than license agreements for software that is generally commercially
available;
(viii) relate to any Affiliate Transaction;
(ix) limit, or purport to limit, in any material respect, the ability of the Company or any of
its Subsidiaries to compete in any line of business or with any Person or in any geographic area or
during any period of time; or
(x) relate to settlement of any material administrative or judicial proceedings.
Each Contract of the type described in clauses (i) through (x) above is referred to herein as a
“Material Contract.”
(b) (i) Each Material Contract is valid and binding on the Company and any of its
Subsidiaries to the extent it is a party thereto, as applicable, and, as of the date hereof, to the
Knowledge of the Company, each other party thereto, and is in full force and effect and enforceable
in accordance with its terms, except for such failures that would not, individually or in the
aggregate, have a Company Material Adverse Effect, (ii) the Company and each of its Subsidiaries,
and, as of the date hereof, to the Knowledge of the Company, any other party
31
thereto, has performed all obligations required to be performed by it under each Material
Contract, except where such noncompliance, would not, individually or in the aggregate, have a
Company Material Adverse Effect, and (iii) neither the Company nor any of its Subsidiaries has
received written notice of the existence of any event or condition which constitutes, or, after
notice or lapse of time or both, will constitute, a default on the part of the Company or any of
its Subsidiaries under any such Material Contract, except where such default would not,
individually or in the aggregate, have a Company Material Adverse Effect.
Section
3.20 Finders or Brokers. Except for UBS Securities LLC (the “Company Financial
Advisor”), neither the Company nor any of its Subsidiaries has engaged any investment banker,
broker or finder in connection with the transactions contemplated by this Agreement that might be
entitled to any fee or any commission in connection with or upon consummation of the Offer, the
Merger or the other transactions contemplated hereby. The Company has provided Parent with
information with respect to the fees payable in connection with the transactions contemplated
hereby.
Section
3.21 State Takeover Statutes. The Board of Directors has taken all actions necessary so
that no anti-takeover statute or regulation under the DGCL or other applicable Laws of the State of
Delaware shall be applicable to the execution, delivery or performance of this Agreement, the
consummation of the Offer, the Merger and the other transactions contemplated by this Agreement.
Section
3.22 Rights Agreement. The Company or the Board of Directors, as the case may be, has (i)
taken all necessary actions so that the execution and delivery of this Agreement and the
consummation of the transactions contemplated hereby will not result in a “Distribution Date“ or
“Stock Acquisition Date“ (as defined in the Rights Agreement), result in Parent or the Purchaser
being an “Acquiring Person” (as defined in the Rights Agreement), or result in the rights to
purchase securities issued under the Rights Agreement becoming exercisable and (ii) amended the
Rights Agreement to (A) render it inapplicable to this Agreement and the transactions contemplated
hereby and (B) provide that the “Final Expiration Date” (as defined in the Rights Agreement) shall
occur immediately prior to the Effective Time.
Section
3.23 Insurance. Except as would not, individually or in the aggregate, have a Company Material
Adverse Effect, the Company and its Subsidiaries maintain insurance coverage, copies of which have
been previously provided to Parent, with reputable insurers in such amounts and covering such risks
as are in accordance with normal industry practice for companies engaged in businesses similar to
that of the Company and its Subsidiaries (taking into account the cost and availability of such
insurance). Except as would not, individually or in the aggregate, have a Company Material Adverse
Effect, such policies are valid and in full force and effect and neither the Company nor any
Subsidiary has received notice denying or disputing any claim (or coverage with respect thereto)
made by the Company or any Subsidiary or regarding the termination, cancellation or amendment, or
premium increase with respect to, any such policy in the last two years. None of the insurance
coverage limits under any such insurance policy have been exhausted, and the existing insurance
coverage is reasonably expected to be materially sufficient to insure the Company against all
pending Actions and other known contingent liabilities, in each case which by their nature would
reasonably be expected to be covered by insurance (subject to deductibles or self insurance
retentions).
32
Section
3.24 Foreign Corrupt Practices Act. Except as would not, individually or in the aggregate, have
a Company Material Adverse Effect, none of the Company, or any of its Subsidiaries, nor, to the
Knowledge of the Company, any director, officer, agent, employee or other Person acting on behalf
of the Company, or any of its Subsidiaries has, in the course of its actions for, or on behalf of,
any of them (i) used any corporate funds for any unlawful contribution, gift, entertainment or
other unlawful expenses relating to political activity; (ii) made any direct or indirect unlawful
payment to any foreign or domestic government official or employee from corporate funds; (iii)
violated any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended; or (iv) made
any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any
foreign or domestic government official or employee.
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF PARENT AND THE PURCHASER
REPRESENTATIONS AND WARRANTIES OF PARENT AND THE PURCHASER
Except as disclosed in the disclosure letter delivered by Parent to the Company immediately
prior to the execution of this Agreement (the “Parent Disclosure Letter”, it being agreed
that disclosure in any section of the Parent Disclosure Letter shall also be deemed disclosure with
respect to any other section of this Agreement as to which the relevance of such section is
reasonably apparent), Parent and the Purchaser jointly and severally represent and warrant to the
Company as follows:
Section
4.1 Qualification; Organization.
(a) Parent is a limited liability company duly organized, validly existing and in good
standing under the Laws of the State of Delaware. The Purchaser is a corporation duly
incorporated, validly existing and in good standing under the Laws of the State of Delaware. Each
of Parent and the Purchaser has all requisite limited liability company or corporate (as
applicable) power and authority to own, lease and operate its properties and assets and to carry on
its business as presently conducted.
(b) Each of Parent and the Purchaser is duly qualified to do business and is in good standing
as a foreign limited liability company or foreign corporation (as applicable) in each jurisdiction
where the ownership, leasing or operation of its assets or properties or conduct of its business
requires such qualification, except where the failure to be so qualified or in good standing would
not, individually or in the aggregate, have a Parent Material Adverse Effect. The organizational
or governing documents of Parent and the Purchaser, as previously provided to the Company, are in
full force and effect. Neither Parent nor the Purchaser is in violation of its organizational or
governing documents.
Section
4.2 Corporate Authority Relative to This Agreement; No Violation.
(a) Each of Parent and the Purchaser has all requisite limited liability company or corporate
(as applicable) power and authority to enter into and perform its obligations under this Agreement
and to consummate the transactions contemplated by this Agreement. The execution, delivery and
performance of this Agreement, and the consummation of the transactions contemplated by this
Agreement, have been duly and validly authorized by
33
the board of managers of Parent and the board
of directors of the Purchaser and no other limited liability company or corporate proceedings on the part of Parent or the Purchaser are
necessary to authorize the consummation of the transactions contemplated hereby (other than the
filing of the Certificate of Merger with the Secretary of State of the State of Delaware). This
Agreement has been duly and validly executed and delivered by Parent and the Purchaser and,
assuming this Agreement constitutes the valid and binding agreement of the Company, this Agreement
constitutes the valid and binding agreement of Parent and the Purchaser, enforceable against each
of Parent and the Purchaser in accordance with its terms, subject to the effects of bankruptcy,
insolvency, fraudulent conveyance, reorganization, moratorium and other similar Laws relating to or
affecting creditors’ rights generally, general equitable principles (whether considered in a
proceeding in equity or at Law) and any implied covenant of good faith and fair dealing.
(b) Other than in connection with or in compliance with (i) the provisions of the DGCL, (ii)
the Exchange Act, (iii) the HSR Act or any applicable Other Antitrust Law, and (iv) the approvals
set forth in Section 4.2(b) of the Parent Disclosure Letter (clauses (i) through (iv),
collectively, the “Parent Approvals”), no authorization, consent, approval or order of, or
filing with, or notice to, any Governmental Entity is necessary, under applicable Law, in
connection with the execution, delivery and performance of this Agreement by Parent or the
Purchaser or the consummation by Parent or the Purchaser of the transactions contemplated by this
Agreement, except for such authorizations, consents, approvals, orders, filings or notices that, if
not obtained or made, would not, individually or in the aggregate, have a Parent Material Adverse
Effect.
(c) The execution, delivery and performance by Parent and the Purchaser of this Agreement does
not, and the consummation of the transactions contemplated hereby and compliance with the
provisions hereof will not, (i) result in any breach or violation of, or default (with or without
notice or lapse of time, or both) under, require consent under, or give rise to a right of
termination, cancellation, modification or acceleration of any obligation or to the loss of any
benefit under any loan, guarantee of indebtedness or credit agreement, note, bond, mortgage,
indenture, lease, agreement, contract, purchase or sale order, instrument, permit, concession,
franchise, right or license binding upon Parent, the Purchaser or any of their Subsidiaries or
result in the creation of any Lien upon any of the properties, assets or rights of Parent, the
Purchaser or any of their Subsidiaries, (ii) conflict with or result in any violation of any
provision of the certificate of formation or operating agreement of Parent, the certificate of
incorporation or bylaws or the Purchaser, or other equivalent organizational documents of Parent,
the Purchaser or any of its Subsidiaries or (iii) assuming that all Parent Approvals are duly
obtained, conflict with or violate in any applicable Laws, other than, in the case of clauses (i)
and (iii), as would not, individually or in the aggregate, have a Parent Material Adverse Effect.
Section
4.3 Offer Documents; Proxy Statement.
(a) The Offer Documents will not, when filed with the SEC, at the time of distribution or
dissemination thereof to the stockholders of the Company, and at the Expiration Date, contain any
untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary in order to make the statements therein, in light of the circumstances under
which they are made, not misleading; provided that no representation or warranty is made by Parent
or the Purchaser with respect to information supplied by or related
34
to, or the sufficiency of
disclosure related to, the Company or any Company Subsidiary. The Offer Documents will comply as to form in all material respects with the provisions of the
Exchange Act and any other applicable federal securities laws.
(b) None of the information supplied or to be supplied by Parent or the Purchaser for
inclusion or incorporation by reference in the Proxy Statement, if any, will at the time of the
mailing of the Proxy Statement to the stockholders of the Company, at the time of the Company
Meeting, and at the time of any amendments thereof or supplements thereto, contain any untrue
statement of a material fact or omit to state any material fact required to be stated therein or
necessary in order to make the statements therein, in light of the circumstances under which they
were made, not misleading.
Section
4.4 Sufficiency of Funds. Parent has delivered to the Company a true and complete copy of
an executed commitment letter from JLL Partners Fund V, L.P. and JLL Partners Fund VI, L.P.
(collectively, the “JLL Funds”) to provide equity financing in an aggregate amount of up to
two hundred and fifty million dollars ($250,000,000) (the “Equity Funding Letter”). The
Equity Funding Letter, in the form so delivered, is in full force and effect and is a legal, valid
and binding obligation of each of the JLL Funds (and the Company has been designated as a
third-party beneficiary thereof). No event has occurred which, with or without notice, lapse of
time or both, would constitute a default or breach on the part of Parent under the Equity Funding
Letter. Parent will have at the Closing sufficient immediately available funds necessary to
consummate all the transactions contemplated by this Agreement, to pay in cash the aggregate Offer
Price on the Expiration Date, the aggregate Merger Consideration and the aggregate RSU
Consideration on the Closing Date and such amount of consideration as may be necessary to satisfy
the Company’s obligations under the indenture dated August 11, 2004 by and between the Company and
U.S. Bank, National Association (formerly Wachovia Bank, National Association) after the Expiration
Date, and to perform Parent’s other obligations under this Agreement (including paying all fees and
expenses related to the transactions contemplated by this Agreement and payable by Parent), all
upon the terms and subject to the conditions set forth herein. Parent acknowledges that its
obligations under this Agreement are not contingent or conditioned in any manner on obtaining any
financing.
Section
4.5 Ownership and Operations of the Purchaser. As of the date of this Agreement, the
authorized capital stock of the Purchaser consists solely of 1,000 shares of common stock, par
value $0.001 per share, all of which are validly issued and outstanding. All of the issued and
outstanding capital stock of the Purchaser is, and at the Effective Time will be, owned by Parent
or a direct or indirect wholly-owned Subsidiary of Parent. The Purchaser has not conducted any
business other than (x) incident to its formation for the sole purpose of carrying out the
transactions contemplated by this Agreement and (y) in relation to this Agreement, the Merger and
the other transactions contemplated hereby and the financing of such transactions.
Section
4.6 Finders or Brokers. Neither Parent nor any of its Subsidiaries has engaged any
investment banker, broker or finder in connection with the transactions contemplated by this
Agreement who, if the Offer and/or the Merger are not consummated, might be entitled to any fee or
any commission from the Company.
35
Section
4.7 Litigation. There are no actions, suits or proceedings pending or, to the Knowledge
of Parent, threatened against Parent or any of its Subsidiaries that would, individually or in the
aggregate, have a Parent Material Adverse Effect. Neither Parent nor any of its Subsidiaries nor
any of their respective properties is or are subject to any order that would, individually or in
the aggregate, have a Parent Material Adverse Effect.
Section
4.8 Solvency. As of the Effective Time, assuming (a) satisfaction of the conditions to
Parent’s obligation to consummate the Merger as set forth herein, or the waiver of such conditions,
and (b) the accuracy of the representations and warranties of the Company set forth in Article III
hereof (for such purposes, such representations and warranties shall be true and correct in all
material respects without giving effect to any knowledge, materiality or “Company Material Adverse
Effect” qualification or exception), (c) any estimates, projections or forecasts of the Company and
its Subsidiaries provided by the Company to Parent have been prepared in good faith based upon
reasonable assumptions and (d) the repayment of the Convertible Notes in accordance with their
terms, as contemplated by this Agreement, immediately after giving effect to all of the
transactions contemplated by this Agreement, including, without limitation, the payment of the
aggregate Offer Price, Merger Consideration and RSU Consideration, and payment of all related fees
and expenses, the Surviving Corporation will be Solvent.
Section
4.9 No Other Information. Parent and the Purchaser acknowledge that the Company makes no
representations or warranties as to any matter whatsoever except as expressly set forth in Article
III. The representations and warranties set forth in Article III are made solely by the Company,
and no Representative of the Company shall have any responsibility or liability related thereto.
Without limiting the generality of the foregoing, each of Parent and the Purchaser agree that: (A)
the Company has not made any representation or warranty to Parent, the Purchaser or any of their
Representatives or Affiliates with respect to: (i) any projections, forecasts or other estimates,
plans or budgets of future revenues, expenses or expenditures, future results of operations (or any
component thereof), future cash flows (or any component thereof) or future financial condition (or
any component thereof) of the Company or any of its Subsidiaries or the future business, operations
or affairs of the Company or any of its Subsidiaries heretofore or hereafter delivered to or made
available to Parent, the Purchaser or their respective Representatives or Affiliates; provided,
however, that the foregoing clause (A)(i) shall not be construed to limit or otherwise affect the
interpretation of the representations and warranties of the Company set forth in Article III; or
(ii) any other information, statement or documents heretofore or hereafter delivered to or made
available to Parent, the Purchaser or their respective Representatives or Affiliates, except to the
extent and as expressly covered by a representation and warranty made by the Company and contained
in Article III; and (B) it has not relied upon any information in clause (A) above.
Section
4.10 Access to Information; Disclaimer. Parent and the Purchaser each acknowledge and
agree that it (a) has had an opportunity to discuss the business of the Company and its
Subsidiaries with the management of the Company, (b) has had reasonable access to (i) the books and
records of the Company and its Subsidiaries and (ii) the electronic dataroom maintained by the
Company for purposes of the transactions contemplated by this Agreement, (c) has been afforded the
opportunity to ask questions of and receive answers from officers of the Company and (d) has
conducted its own independent investigation of the Company and its
36
Subsidiaries, their respective businesses and the transactions contemplated hereby, and has
not relied on any representation, warranty or other statement by any Person on behalf of the
Company or any of its Subsidiaries, other than the representations and warranties of the Company
expressly contained in Article III of this Agreement and that all other representations and
warranties are specifically disclaimed.
ARTICLE V
COVENANTS AND AGREEMENTS
COVENANTS AND AGREEMENTS
Section
5.1 Conduct of Business.
(a) From and after the date hereof and prior to the earlier of the Effective Time and the
date, if any, on which this Agreement is terminated pursuant to Section 7.1 (the “Termination
Date”), and except (i) as may be otherwise required by applicable Law, (ii) with the prior
written consent of Parent (not to be unreasonably withheld, delayed or conditioned), (iii) as
expressly permitted or required by this Agreement or (iv) as disclosed in Section 5.1 of the
Company Disclosure Letter, the Company shall, and shall cause each of its Subsidiaries to, (1)
conduct its business in all material respects in the ordinary course consistent with past practice,
and (2) use commercially reasonable efforts to maintain and preserve intact its business
organization and business relationships, to preserve its assets, rights and properties in good
repair and condition and to retain the services of its key officers and key employees in each case,
in all material respects.
(b) Without limiting the foregoing, the Company agrees with Parent that between the date
hereof and the earlier of the Effective Time and the Termination Date, except as set forth in
Section 5.1 of the Company Disclosure Letter or as otherwise expressly permitted or required by
this Agreement, the Company shall not, and shall not permit any of its Subsidiaries to, without the
prior written consent of Parent (not to be unreasonably withheld, delayed or conditioned):
(i) adjust, split, combine or reclassify any capital stock or other equity interests or
otherwise amend the terms of its capital stock or other equity interests, or modify the rights of
the holders thereof;
(ii) make, declare or pay any dividend, or make any other distribution on, or directly or
indirectly redeem, purchase or otherwise acquire or encumber, any shares of its capital stock or
other equity interests or any securities or obligations convertible (whether currently convertible
or convertible only after the passage of time or the occurrence of certain events) into or
exchangeable for any shares of its capital stock or other equity interests, except in connection
with the exercise of stock options or settlement of other awards or obligations outstanding as of
the date hereof; provided that this Section 5.1(b)(ii) shall not apply to dividends or
distributions paid in cash by Subsidiaries to the Company or to other wholly owned Subsidiaries;
(iii) grant any Person any right to acquire any shares of its capital stock or other equity
interests;
37
(iv) issue or sell any additional shares of capital stock or other equity interests, any
securities convertible into, or any rights, warrants or options to acquire, any such shares of
capital stock or other equity interests, except pursuant to the exercise of conversion rights of
currently outstanding securities, the exercise of stock options or settlement of other awards
outstanding as of the date hereof or as required under any Company Benefit Plan;
(v) except with respect to the repayment of Indebtedness, as and to the extent provided in
Section 5.1 of the Company Disclosure Letter, sell, lease, license, transfer, mortgage, abandon,
encumber or otherwise subject to a Lien or otherwise dispose of, in whole or in part, any
properties, rights or assets having a value in excess of five hundred thousand dollars ($500,000)
individually or one million dollars ($1,000,000) in the aggregate (other than (x) sales of
inventory in the ordinary course of business, consistent with past practice, (y) commodity, sale or
hedging agreements which can be terminated on ninety (90) days or less notice without penalty, in
each case in the ordinary course of business consistent with past practice, as described in Section
5.1 of the Company Disclosure Letter, or (z) the sale of the Company’s real property located in
Miami, Florida);
(vi) make any capital expenditures (or authorization or commitment with respect thereto) in a
manner reasonably expected to cause expenditures to exceed by more than five hundred thousand
dollars ($500,000) the respective amounts set forth in the Company’s budget previously made
available to Parent;
(vii) except (i) in connection with the refinancing of existing Indebtedness under the
Company’s current revolving credit facility at the maturity thereof, for which the terms of the new
Indebtedness shall be subject to the prior written consent of Parent (not to be unreasonably
withheld, conditioned or delayed), (ii) for borrowings in the ordinary course of business,
consistent with past practice, under any credit facility put in place by the Company in connection
with the refinancing of existing Indebtedness under the Company’s current revolving credit facility
at the maturity thereof or (iii) in connection with outstanding surety bonds or surety bonds
entered into in the ordinary course of business, incur, create, assume or otherwise become liable
for, or repay or prepay, any indebtedness for borrowed money (other than indebtedness related to
intercompany borrowing) (including the issuance of any debt security), any capital lease
obligations, any guarantee of any such indebtedness or debt securities of any other Person, or any
“keep well” or other agreement to maintain any financial statement condition of another Person
(such obligations collectively, “Indebtedness”), or amend, modify or refinance any existing
Indebtedness, other than at the maturity thereof;
(viii) make any acquisition of another Person or business, whether by merger, purchase of
stock or securities, contributions to capital, loans to, property transfers, or entering into
binding agreements with respect to any such investment or acquisition (including any conditional or
installment sale Contract or other retention Contract relating to purchased property);
(ix) except in the ordinary course of business consistent with past practice, enter into,
renew, extend, materially amend, cancel or terminate any Contract that is a Material Contract or a
Contract which if entered into prior to the date hereof would be a Material
38
Contract, in each case, other than any Contract that would be permitted under any other
clauses of this Section 5.1(b);
(x) except in the case of new hires and terminations of employees, in each case, in the
ordinary course of business, consistent with past practice, enter into or amend any employment,
severance, termination or other agreement; provided, that no severance arrangement entered into in
connection with any such new hire shall provide for, and no terminated employee shall be entitled
to receive, severance payments in excess of seventy-five thousand dollars ($75,000);
(xi) except as required by Law or by Contracts in existence as of the date hereof or by the
Company Benefit Plans, (A) increase the compensation or benefits of any of its employees,
independent contractors or directors, other than increases in the ordinary course of business,
consistent with past practice, which for this purpose means that any such compensation increase
shall be consistent with the timing and calculation of past compensation increases, shall be based
on the same performance and other criteria used for past compensation increases and shall be
proportionate in amount to past compensation increases, (B) amend or adopt any compensation or
benefit plan including any pension, retirement, profit-sharing, bonus or other employee benefit or
welfare benefit plan (other than any such adoption or amendment that does not materially increase
in the aggregate the cost to the Company or any of its Subsidiaries of maintaining the applicable
compensation or benefit plan) with or for the benefit of its employees, independent contractors or
directors, or (C) accelerate the vesting or exercisability of, or the lapsing of restrictions with
respect to, any stock options or other stock-based compensation;
(xii) except with respect to Taxes (which are covered in clause (xx)), compromise, settle or
agree to settle any suit, action, claim, proceeding or investigation (including any suit, action,
claim, proceeding or investigation relating to this Agreement or the transactions contemplated
hereby), or consent to the same, other than compromises, settlements or agreements in the ordinary
course of business consistent with past practice that involve only the payment of monetary damages
(x) not in excess of two hundred fifty thousand dollars ($250,000) individually or five hundred
thousand dollars ($500,000) in the aggregate or (y) consistent with the reserves reflected in the
Company’s balance sheet at September 30, 2008, in any case without the imposition of material
equitable relief on, or the admission of wrongdoing by, the Company or any of its Subsidiaries;
(xiii) amend or waive any material provision of the Company Charter or its by-laws or other
equivalent organizational documents;
(xiv) except in accordance with Section 1.3(a), modify the size of the Board of Directors;
(xv) enter into any new line of business outside of its existing business and reasonable
extensions thereof;
(xvi) take any action to render inapplicable, or to exempt any third party from any
anti-takeover Laws or the Rights Agreement;
39
(xvii) enter into any new lease or amend the terms of any existing lease of real property
which would require payments over the remaining term of such lease in excess of five hundred
thousand dollars ($500,000) (excluding any renewal terms), except as otherwise required in the
ordinary course of business or as set forth in the Company’s budget previously made available to
Parent;
(xviii) adopt or enter into a plan of complete or partial liquidation, dissolution, merger,
consolidation, restructuring, recapitalization or other reorganization of such entity (other than
among wholly owned Subsidiaries);
(xix) implement or adopt any material change in its financial accounting principles, practices
or methods, other than as required by GAAP, the Company’s outside auditors, applicable Law or
regulatory guidelines;
(xx) except to the extent any such settlement or compromise is consistent with reserves
reflected in the Company’s balance sheet at September 30, 2008, change any material method of Tax
accounting, enter into any closing agreement with respect to material Taxes, settle or compromise
any material liability for Taxes, make, revoke or change any material Tax election, file or
surrender any claim for a material refund of Taxes or file any material amended Tax Return, in each
case other than in the ordinary course of business consistent with past practice; or
(xxi) agree to take, make any commitment to take, or adopt any resolutions of its Board of
Directors in support of any of the actions prohibited by this Section 5.1(b).
(c) From and after the date hereof and prior to the earlier of the Effective Time or the
Termination Date, and except (i) as may be otherwise required by applicable Law or (ii) as
expressly contemplated or permitted by this Agreement, no party shall take, or permit any of its
Affiliates to take, any action which is intended to or which would reasonably be expected to
materially adversely affect or materially delay the ability of such party from obtaining any
necessary approvals of any Governmental Entity required for the transactions contemplated hereby,
performing its covenants and agreements under this Agreement or consummating the transactions
contemplated hereby or otherwise materially delay or prohibit consummation of the Merger or the
other transactions contemplated hereby.
Section
5.2 No Solicitation.
(a) Subject to Section 5.2(c), the Company agrees that neither it nor any Subsidiary of the
Company shall, and that it shall use its reasonable best efforts to ensure that its and their
respective officers, directors, employees, agents and representatives, including any investment
banker, attorney or accountant retained by it or any of its Subsidiaries
(“Representatives”), do not, directly or indirectly, (i) initiate, solicit, knowingly
encourage (including by providing information) or knowingly facilitate any inquiries, proposals or
offers with respect to, or the making or completion of, an Alternative Proposal or any inquiry,
proposal or offer that is reasonably likely to lead to an Alternative Proposal, (ii) engage,
continue or participate in any negotiations concerning, or provide or cause to be provided any
information or
40
data relating to the Company or any of its Subsidiaries in connection with, or have any
discussions (other than to state that they are not permitted to have discussions and to refer to
this Agreement) with any Person relating to, or that is reasonably likely to lead to, an actual or
proposed Alternative Proposal, (iii) approve, endorse or recommend, or propose publicly to approve,
endorse or recommend, any Alternative Proposal, (iv) execute or enter into any letter of intent,
agreement in principle, merger agreement, stock purchase agreement, acquisition agreement, option
agreement or other similar agreement relating to any Alternative Proposal, (v) waive any standstill
or similar provision in any confidentiality or other agreement to which the Company or any of its
Subsidiaries is a party or (vi) resolve to propose or agree to do any of the foregoing; provided,
however, it is understood and agreed that any determination or action by the Board of Directors
permitted under Section 5.2(c), Section 5.2(d) or Section 7.1(c)(iii), shall not, in and of itself,
be deemed to be a breach or violation of this Section 5.2(a) or, in the case of Section 5.2(c),
give Parent a right to terminate this Agreement pursuant to Section 7.1(d)(ii).
(b) The Company shall, shall cause each of its Subsidiaries to, and shall use its reasonable
best efforts to cause each of its and their respective Representatives to, immediately cease any
solicitations, discussions or negotiations with any Person (other than the parties hereto) that has
made or indicated an intention to make an Alternative Proposal, in each case that exist as of the
date hereof, and shall request the prompt return or destruction of all confidential information
previously furnished in connection therewith.
(c) Notwithstanding anything to the contrary in Section 5.2(a) or Section 5.2(b), at any time
prior to the Acceptance Time, the Company may, in response to an unsolicited written Alternative
Proposal received after the date hereof which the Board of Directors determines in good faith,
after consultation with outside counsel and the Company’s financial advisor, constitutes or is
reasonably expected to lead to a Superior Proposal, and subject to the Board of Directors
determining, after consultation with its outside counsel, that the failure to take such action
would be inconsistent with its fiduciary duties under applicable Law, (i) furnish non-public
information with respect to the Company and its Subsidiaries to the Person making such Alternative
Proposal and its Representatives and potential debt and equity financing sources pursuant to a
confidentiality agreement with terms no less favorable to the Company in the aggregate than the
Confidentiality Agreement, including any standstill or similar covenants to which Parent is
subject, and (ii) participate in discussions or negotiations with such Person and its respective
Representatives regarding such Alternative Proposal; provided, however, that prior to furnishing
information to, or engaging in negotiations or discussions with, any Person, the Company shall
comply with Section 5.2(e); provided, further, that the Company shall provide or make available to
Parent any non-public information concerning the Company or any of its Subsidiaries that is
provided to the Person making such Alternative Proposal or its Representatives which was not
previously provided or made available to Parent prior to or concurrently with or as soon as
practicable after providing such information to such other Person.
(d) Except as set forth in Section 7.1(c)(iii) or this Section 5.2(d), neither the Board of
Directors nor any committee thereof shall (i) withdraw or modify in a manner adverse to Parent or
the Purchaser, or publicly propose to withdraw or modify in a manner adverse to Parent or the
Purchaser, the Recommendation, (ii) approve or recommend any letter of intent, agreement in
principle, acquisition agreement, stock purchase agreement, option agreement or
41
similar agreement constituting or relating to, or that is intended to be or would reasonably
be likely to result in, any Alternative Proposal or (iii) approve or recommend, or publicly propose
to approve or recommend, any Alternative Proposal. Notwithstanding the foregoing, if, prior to the
Acceptance Time, the Board of Directors determines in good faith, (A) after consultation with
outside counsel and the Company’s financial advisor, that an unsolicited written Alternative
Proposal received by the Company constitutes a Superior Proposal (after complying with, and giving
effect to any commitments offered by Parent pursuant to this Section 5.2(d) or Section 7.1(c)(iii),
and (B) after consultation with outside counsel, that the failure to take such action would be
inconsistent with the Board of Directors’ exercise of its fiduciary duties under applicable Law,
the Board of Directors or any committee thereof may withdraw, or modify or qualify its
Recommendation (a “Change of Recommendation”); provided, however, that prior to a Change of
Recommendation, (A) the Board of Directors shall have determined that it has received a Superior
Proposal, (B) the Company shall have notified Parent and the Purchaser in writing of the Board of
Directors’ intention to make a Change of Recommendation pursuant to this Section 5.2(d), and
included with such notice the identity of the Person making such proposal, the most current written
agreement relating to the transaction that constitutes such Superior Proposal and all related
transaction agreements, (C) the Company and its Representatives shall have negotiated in good faith
with Parent and the Purchaser (to the extent Parent and the Purchaser desire to negotiate) to make
adjustments to the terms and conditions of this Agreement so that the Alternative Proposal no
longer constitutes a Superior Proposal, and (D) at least five (5) Business Days following both the
receipt by Parent and the Purchaser of the notice referred to in clause (B) above and the
initiation of good faith negotiations referred to in clause (C) above, and taking into account any
revised proposal committed to by Parent and the Purchaser since receipt of the notice referred to
in clause (B) above, the Board of Directors shall have determined in good faith, after consultation
with outside counsel and the Company’s financial advisor, that such Superior Proposal continues to
be more favorable to the Company and its stockholders from a financial point of view than the
revised proposal committed to by Parent and the Purchaser, if any.
(e) The Company promptly (and in any event within 48 hours) shall advise Parent orally and in
writing of (i) any inquiries, proposals or offers regarding any Alternative Proposal, (ii) any
request for information relating to the Company or its Subsidiaries, other than requests for
information not reasonably expected to be related or lead to an Alternative Proposal, and (iii) any
inquiry or request for discussion or negotiation regarding or that would reasonably be expected to
result in an Alternative Proposal, including in each case the identity of the Person making any
such Alternative Proposal or indication or inquiry or offer or request and the material terms and
conditions of any such Alternative Proposal or indication or inquiry or offer. The Company shall
keep Parent reasonably informed on a reasonably current basis of the status (including any material
changes to the terms thereof) of any such discussions or negotiations regarding any such
Alternative Proposal or indication or inquiry or offer or any material developments relating
thereto (the Company agreeing that it shall not, and shall cause its Subsidiaries not to, enter
into any confidentiality agreement with any Person subsequent to the date of this Agreement which
prohibits the Company from providing such information to Parent but it being agreed that the third
party financing sources may impose confidentiality restrictions on the Company with respect to
their proposed financing).
42
(f) Nothing contained in this Agreement shall prohibit the Company or its Board of Directors
from (i) disclosing to its stockholders a position contemplated by Rules 14d-9 and 14e-2(a)
promulgated under the Exchange Act or (ii) making any required disclosure to the Company’s
stockholders if, in the good faith judgment of such Board of Directors, after consultation with its
outside counsel, it is required to do so under applicable Law; provided, however, that in no event
shall this Section 5.2(f) affect the obligations of the Company specified in Section 5.2(d) or
Section 5.2(e) and provided, further that, any such disclosure (other than a “stop, look and
listen” communication or similar communication of the type contemplated by Section 14d-9(f) under
the Exchange Act) which would otherwise constitute a Change of Recommendation shall only be deemed
to be a Change of Recommendation if the Board of Directors fails to expressly publicly reaffirm its
Recommendation within five (5) Business Days after such disclosure.
(g) The Company shall not take any action to (i) exempt any Person (other than Parent, the
Purchaser and their respective Affiliates) from the restrictions on “business combinations”
contained in Section 203 of the DGCL (or any similar provisions of any other Law) or otherwise
cause such restrictions not to apply or (ii) terminate, amend, modify, make any determination under
or waive any provision of the Rights Agreement, in each case unless such actions are taken
simultaneously with a termination of this Agreement pursuant to Section 7.1(c)(iii).
(h) As used in this Agreement, “Alternative Proposal” shall mean any bona fide
inquiry, proposal or offer from any Person or group of Persons other than Parent or one of its
Affiliates relating to, in a single transaction or series of related transactions, (i) a merger,
reorganization, consolidation, share exchange, business combination, recapitalization, liquidation,
dissolution or similar transaction involving a direct or indirect acquisition of the Company (or
any Subsidiary or Subsidiaries of the Company whose business constitutes 20% or more of the net
revenues, net income or assets (based on fair market value) of the Company and its Subsidiaries,
taken as a whole) or (ii) the acquisition (including by way of tender or exchange offer) in any
manner, directly or indirectly, of over 20% of (x) the issued and outstanding Company Common Stock
or (y) the consolidated total assets (based on fair market value) of the Company and its
Subsidiaries, in each case other than the Merger.
(i) As used in this Agreement, “Superior Proposal” shall mean any Alternative Proposal
on terms which the Board of Directors determines in good faith, after consultation with outside
counsel and the Company’s financial advisor, to be more favorable from a financial point of view to
the holders of Company Common Stock than the Merger to be effected pursuant to this Agreement,
taking into account its consultation with outside counsel and the Company’s financial advisor and
all the terms and conditions of such proposal (including all legal, financial (including financing
terms), regulatory and other aspects of such Alternative Proposal, as well as the likelihood and
timing of consummation thereof) and this Agreement (including any changes to the terms of this
Agreement committed to by Parent in good faith to the Company in response to such proposal or
otherwise); provided that for purposes of the definition of “Superior Proposal”, the references to
“20%” in the definition of Alternative Proposal shall be deemed to be references to “50%.”
43
Section
5.3 Employee Matters; Equity Awards.
(a) For a period of one (1) year following the Effective Time, Parent shall provide, or shall
cause to be provided, to each current employee of the Company and its Subsidiaries (“Company
Employees”) who remains employed by the Company or any of its Subsidiaries annual base salary
and base wages, cash incentive compensation opportunities (excluding equity-based compensation) and
benefits that are in the aggregate comparable to such annual base salary and base wages, cash
incentive compensation opportunities (excluding equity-based compensation) and benefits provided to
such Company Employees immediately prior to the Effective Time. Notwithstanding any other
provision of this Agreement to the contrary, the Surviving Corporation may terminate the employment
of any Company Employee at any time, provided that Parent shall or shall cause the Surviving
Corporation to provide Company Employees whose employment terminates during the one-year period
following the Effective Time with severance benefits at the levels and pursuant to the terms of the
Company’s severance plans as in effect immediately prior to the Effective Time. During such
one-year period following the Effective Time, severance benefits offered to Company Employees
thereunder shall be determined without taking into account any reduction after the Effective Time
in base salary or base wages paid to Company Employees and taking into account the service
crediting provisions set forth in Section 5.3(b) below.
(b) For purposes of vesting and eligibility to participate under the employee benefit plans of
Parent and its Subsidiaries providing benefits to any Company Employees after the Effective Time
(including the Company Benefit Plans) (the “New Plans”), each Company Employee shall be
credited with his or her years of service with the Company and its Subsidiaries and their
respective predecessors before the Effective Time, to the same extent as such Company Employee was
entitled, before the Effective Time, to credit for such service under any similar Company employee
benefit plan in which such Company Employee participated or was eligible to participate immediately
prior to the Effective Time. In addition, and without limiting the generality of the foregoing, to
the extent legally permissible, (i) each Company Employee shall be immediately eligible to
participate, without any waiting time, in any and all New Plans to the extent coverage under such
New Plan is replacing comparable coverage under a Company Benefit Plan in which such Company
Employee participated immediately before the Effective Time (such plans, collectively, the “Old
Plans”), and (ii) for purposes of each New Plan providing medical, dental, pharmaceutical
and/or vision benefits to any Company Employee, Parent shall cause all pre-existing condition
exclusions and actively-at-work requirements of such New Plan to be waived for such employee and
his or her covered dependents, unless such conditions would not have been waived under the
corresponding Old Plans of the Company or its Subsidiaries in which such employee participated
immediately prior to the Effective Time and Parent shall cause any eligible expenses incurred by
such employee and his or her covered dependents during the portion of the plan year of the Old Plan
ending on the date such employee’s participation in the corresponding New Plan begins to be taken
into account under such New Plan for purposes of satisfying all deductible, coinsurance and maximum
out-of-pocket requirements applicable to such employee and his or her covered dependents for the
applicable plan year as if such amounts had been paid in accordance with such New Plan.
44
(c) From and after the Effective Time, Parent shall cause the Surviving Corporation and its
Subsidiaries to perform all their duties, obligations and commitments under each Company Employment
Agreement as in effect immediately prior to the Effective Time (except as may otherwise be agreed
between or among the applicable parties to such agreement), including (without limitation) the
compensation payments, employee benefits, reimbursements perquisites and allowances provided
thereunder and any severance benefits that become payable in accordance with the terms of such
Company Employment Agreement. From and after the Effective Time, Parent shall also cause the
Surviving Corporation and its Subsidiaries to honor all obligations under all other Company Benefit
Plans and compensation and severance arrangements and agreements in accordance with their terms as
in effect immediately before the Effective Time, provided that, subject to the requirements of
Section 5.3(a), nothing herein shall prohibit the Surviving Corporation from amending or
terminating any particular Company Benefit Plan to the extent permitted by its terms or applicable
Law.
(d) The provisions of this Section 5.3 are solely for the benefit of the parties to this
Agreement, and no current or former employee shall be regarded for any purpose as a third party
beneficiary of this Agreement and nothing herein shall be construed as an amendment to any Company
Benefit Plan for any purpose.
Section
5.4 Required Approvals.
(a) Subject to the terms and conditions set forth in this Agreement, each of the parties
hereto shall use its reasonable best efforts to take, or to cause to be taken, all actions, to
file, or cause to be filed, all documents and to do, or to cause to be done, and to assist, to
cooperate and, in the case of Parent, to cause the members of the Parent Group to cooperate with
the other parties in doing, all things necessary, proper or advisable to consummate and make
effective the transactions contemplated by this Agreement, including using reasonable best efforts
to accomplish the following: (i) the obtaining as promptly as practicable of all necessary actions
or nonactions, waivers, consents, clearances, approvals, and expirations or terminations of waiting
periods, including the Company Approvals and the Parent Approvals, from any Governmental Entities
and the making of all necessary registrations and filings and the taking of all steps as may be
necessary to obtain an approval, clearance or waiver from, or to avoid an action or proceeding by,
any Governmental Entity, (ii) the obtaining as promptly as practicable of all necessary consents,
approvals or waivers from any third parties in connection with the consummation of the Offer, the
Merger and the other transactions contemplated hereby, (iii) the defending of any lawsuits or other
legal proceedings, whether judicial or administrative, challenging this Agreement or the
consummation of the Offer, the Merger and the other transactions contemplated hereby, and (iv) the
execution and delivery of any additional instruments necessary to consummate the Offer, the Merger
and the other transactions contemplated hereby; provided, however, that neither the Company nor any
of its Subsidiaries shall commit to the payment of any fee, penalty or other consideration in
connection with obtaining any consent without the prior consent of Parent.
(b) Subject to the terms and conditions herein provided and without limiting the foregoing,
the Company and Parent shall (i) promptly, but in no event later than five (5) Business Days after
the date hereof, file any and all Notification and Report Forms required under the HSR Act with
respect to the Offer, the Merger and the other transactions contemplated
45
hereby, and use reasonable best efforts to cause the expiration or termination of any
applicable waiting periods under the HSR Act, (ii) by any applicable legal deadline, file any and
all forms required by any applicable Other Antitrust Law with respect to the Offer, the Merger and
the other transactions contemplated hereby, and use reasonable best efforts to cause the expiration
or termination of any applicable waiting periods thereunder, (iii) use reasonable best efforts to
cooperate with each other and, in the case of Parent, to cause each member of the Parent Group to
cooperate in (x) determining promptly whether any filings are required to be made with, or
consents, permits, authorizations, waivers, clearances, approvals, and expirations or terminations
of waiting periods are required to be obtained from, any third parties or other Governmental
Entities in connection with the execution and delivery of this Agreement and the consummation of
the transactions contemplated hereby and (y) making promptly all such filings and obtaining all
such consents, permits, authorizations or approvals, in each case, as promptly as practicable, (iv)
supply to any Governmental Entity as promptly as reasonably practicable any additional information
or documentary material that may be requested pursuant to any Law or by such Governmental Entity,
and (v) use reasonable best efforts to take promptly, or cause to be taken promptly, all other
actions and do, or cause to be done, all other things necessary, proper or advisable to consummate
and make effective the Offer, the Merger and the other transactions contemplated hereby, as
promptly as practicable, including using reasonable best efforts to take all such further action,
and, in the case of Parent, to cause each member of the Parent Group to take all such further
action, as may be necessary (A) to resolve such objections, if any, as the United States Federal
Trade Commission, the Antitrust Division of the United States Department of Justice, any state
antitrust enforcement authorities or competition authorities of any other nation or other
jurisdiction or any other Person may assert under any Law with respect to the Offer, the Merger and
the other transactions contemplated hereby, and (B) to avoid or eliminate each and every impediment
under any Law that may be asserted by any Governmental Entity with respect to the Merger so as to
enable the Closing to occur as promptly as practicable and in any event no later than the End Date,
including without limitation (x) proposing, negotiating, committing to and effecting, by consent
decree, preservation of assets or other trust, hold separate order or otherwise, the sale,
divestiture or disposition of any assets or businesses of any member of the Parent Group, Parent or
its equityholders or any of their respective Subsidiaries or Affiliates or of the Company or its
Subsidiaries and (y) otherwise taking or committing to take any actions, or, in the case of Parent,
to cause the members of the Parent Group to take any action, that after the Closing would limit the
freedom of the Parent Group, Parent or its Subsidiaries’ (including the Surviving Corporation’s) or
Affiliates’ freedom of action with respect to, or its ability to retain, one or more of its or its
Subsidiaries’ (including the Surviving Corporation’s) or Affiliates’ businesses, product lines or
assets, in each case as may be required in order to avoid the entry of, or to effect the
dissolution of, any injunction, temporary restraining order or other order in any suit or
proceeding which would otherwise have the effect of preventing the Closing or delaying the Closing
beyond the End Date; provided that, neither the Company nor any of its Subsidiaries shall, nor
shall Parent or any of its Subsidiaries or Affiliates be obligated to, become subject to, or
consent or agree to or otherwise take any action with respect to, any requirement, condition,
understanding, agreement or order of a Governmental Entity to sell, to hold separate or otherwise
dispose of, or to conduct, restrict, operate, invest or otherwise change the assets or business of
the Company or any of its Subsidiaries or Parent or any of its Subsidiaries or Affiliates, as the
case may be, unless such requirement, condition, understanding, agreement or order is (I) not a
condition for approval by a Governmental Entity
46
which would have a material adverse effect on the business or operations of the combination of
the Parent Group’s business with the business of the Company as operated on the date of execution
of this Agreement and (II) binding on the Company or Parent, its Subsidiaries or Affiliates,
respectively, only in the event that the Closing occurs.
(c) Subject to applicable legal limitations, the Company and Parent shall keep each other
reasonably apprised of the status of matters relating to the completion of the Merger and the other
transactions contemplated by this Agreement, including promptly furnishing the other with copies of
notices or other written communications received by the Company or Parent, as the case may be, or
any of their respective Subsidiaries or Affiliates, from any third party and/or any Governmental
Entity with respect to the Merger or such transactions. The Company and Parent shall permit
counsel for the other party reasonable opportunity to review in advance, and consider in good faith
the views of the other party in connection with, any proposed written communication to any
Governmental Entity. Each of the Company and Parent agrees that, during the term of this
Agreement, it will not withdraw its filing under the HSR Act or any other applicable Law without
the written consent of the other party, and each of the Company and Parent agrees that it will not
enter into any agreement with any Governmental Entity regarding the Merger or the other
transactions contemplated by this Agreement without the written consent of the other party. To the
extent practicable under the circumstances, each of the Company and Parent agrees not to
participate in any substantive meeting or discussion, either in person or by telephone, with any
Governmental Entity in connection with the proposed transactions unless it consults with the other
party in advance and, to the extent not prohibited by such Governmental Entity, gives the other
party the opportunity to attend and participate.
Section
5.5 Takeover Statute. If any Takeover Statute shall become applicable to the Offer, the
Merger, the Top-Up Option, including the acquisition of the Top-Up Shares pursuant thereto, or the
other transactions contemplated by this Agreement after the date of this Agreement, each of the
Company and Parent and the members of the Company’s Board of Directors and Parent’s board of
managers shall grant such approvals and take such actions as are reasonably necessary so that the
Offer, the Merger, the Top-Up Option, including the acquisition of the Top-Up Shares pursuant
thereto, and the other transactions contemplated hereby may be consummated as promptly as
practicable on the terms contemplated herein and otherwise act to eliminate or minimize the effects
of such Law on the Offer, the Merger, the Top-Up Option, including the acquisition of the Top-Up
Shares pursuant thereto, and the other transactions contemplated hereby. Nothing in this Section
5.5 shall be construed to permit Parent or the Purchaser to do any act that would constitute a
violation or breach of, or a waiver of any of the Company’s rights under, any other provision of
this Agreement.
Section
5.6 Public Announcements. The Company and Parent will consult with and provide each other
the reasonable opportunity to review and comment upon any press release or other public statement
or comment prior to the issuance of such press release or other public statement or comment
relating to this Agreement or the transactions contemplated herein and shall not issue any such
press release or other public statement or comment prior to such consultation except as may be
required by applicable Law or by obligations pursuant to any listing agreement with any national
securities exchange or the Nasdaq. Parent and the Company agree that the press release announcing
the execution and delivery of this Agreement shall be a joint release of, and shall not be issued
prior to the approval of each of, Parent and the Company.
47
Section
5.7 Indemnification and Insurance.
(a) Parent and the Purchaser agree that all rights to exculpation, indemnification and
advancement of expenses for acts or omissions occurring at or prior to the Effective Time, whether
asserted or claimed prior to, at or after the Effective Time, now existing in favor of the current
or former directors, officers or employees, as the case may be, of the Company or its Subsidiaries
as provided in their respective certificates of incorporation or by-laws or other organizational
documents or in any agreement as in effect on the date hereof and which has previously been made
available to Parent shall survive the Merger and shall continue in full force and effect to the
extent provided in the following sentence. Parent and the Surviving Corporation shall maintain in
effect any and all exculpation, indemnification and advancement of expenses provisions of the
Company’s and any of its Subsidiaries’ certificate of incorporation and by-laws or similar
organizational documents in effect immediately prior to the Effective Time or in any agreements of
the Company or its Subsidiaries with any of their respective current or former directors, officers
or employees in effect as of the date hereof and which has previously been provided to Parent, and
shall not, for a period of six years from the date hereof, amend, repeal or otherwise modify any
such provisions in any manner that would adversely affect the rights thereunder of any individuals
who at the Effective Time were current or former directors, officers or employees of the Company or
any of its Subsidiaries and all rights to indemnification thereunder in respect of any Action
pending or asserted or any claim made within such period shall continue until the disposition of
such Action or resolution of such claim.
(b) From and after the Effective Time, the Surviving Corporation shall, to the fullest extent
permitted under applicable Law, indemnify and hold harmless (and advance funds in respect of each
of the foregoing) each current and former director, officer or employee of the Company or any of
its Subsidiaries (each, together with such person’s heirs, executors or administrators, an
“Indemnified Party”) against any costs or expenses (including advancing reasonable
attorneys’ fees and expenses in advance of the final disposition of any Action to each Indemnified
Party to the fullest extent permitted by Law upon the receipt of any customary undertaking required
by the Surviving Corporation), judgments, fines, losses, claims, damages, liabilities and amounts
paid in settlement in connection with any actual or threatened claim, action, suit, proceeding or
investigation, whether civil, criminal, administrative or investigative (an “Action”),
arising out of, relating to or in connection with any action or omission occurring or alleged to
have occurred whether before or at the Effective Time in connection with such Indemnified Party
serving as an officer, director, employee or other fiduciary of the Company or any of its
Subsidiaries or of any entity if such service was at the request or for the benefit of the Company
or any of its Subsidiaries.
(c) For a period of six (6) years from the Effective Time, Parent shall either cause to be
maintained in effect the current policies of directors’ and officers’ liability insurance and
fiduciary liability insurance maintained by the Company and its Subsidiaries or cause to be
provided substitute policies or purchase, or cause the Surviving Corporation to purchase, a “tail
policy,” in either case of at least the same coverage and amounts containing terms and conditions
that are not less advantageous than such policy with respect to matters arising on or before the
Effective Time and from insurance carriers with comparable credit ratings, except that neither
Parent nor the Surviving Corporation shall be required to pay with respect to such insurance
policies in respect of any one policy year more than 250% of the annual premium paid by the
48
Company for such insurance for the fiscal year ended December 31, 2008. At the Company’s
option, the Company may purchase, prior to the Effective Time, a six-year prepaid “tail policy” on
terms and conditions (in both amount and scope) providing substantially equivalent benefits as the
current policies of directors’ and officers’ liability insurance and fiduciary liability insurance
maintained by the Company and its Subsidiaries with respect to matters arising on or before the
Effective Time, covering without limitation the transactions contemplated hereby.
(d) The rights of each Indemnified Party hereunder shall be in addition to, and not in
limitation of, any other rights such Indemnified Party may have under the Company Charter, the
By-laws or other similar organizational documents of the Company or any of its Subsidiaries or the
Surviving Corporation, any other agreement or arrangement, the DGCL or otherwise. The agreements
and covenants contained herein shall not be deemed to be exclusive of any other rights to which any
Indemnified Party is entitled, whether pursuant to Law, contract or otherwise. Nothing in this
Agreement is intended to, shall be construed to or shall release, waive or impair any rights to
directors’ and officers’ insurance claims under any policy that is or has been in existence with
respect to the Company or any of its Subsidiaries or their respective officers, directors and
employees, it being understood and agreed that the indemnification provided for in this Section 5.7
is not prior to, or in substitution for, any such claims under any such policies. The provisions of
this Section 5.7 shall survive the consummation of the Merger and, notwithstanding any other
provision of this Agreement that may be to the contrary, expressly are intended to benefit, and are
enforceable by, each of the Indemnified Parties.
(e) In the event Parent, the Surviving Corporation or any of their respective successors or
assigns (i) consolidates with or merges into any other Person and shall not be the continuing or
surviving corporation or entity in such consolidation or merger or (ii) transfers all or
substantially all of its properties and assets to any Person, then, and in either such case, proper
provision shall be made so that the successors and assigns of Parent or the Surviving Corporation,
as the case may be, shall assume all of the obligations set forth in this Section 5.7.
Section
5.8 Access; Confidentiality. Subject to applicable Law and to any contractual
confidentiality restrictions, the Company shall afford to Parent, and to Parent’s Representatives
and financing sources, reasonable access upon reasonable advance notice during normal business
hours during the period prior to the Effective Time or the termination of this Agreement to all of
its and its Subsidiaries’ properties, Contracts, books and records and to those officers, employees
and agents of the Company to whom Parent reasonably requests access, and, during such period, the
Company shall furnish, as promptly as practicable, to Parent all information concerning its and its
Subsidiaries’ business, properties and personnel and all financial information as Parent may
reasonably request. Except for disclosures expressly permitted by the terms of the Confidentiality
Agreement, Parent shall hold, and shall cause its Representatives to hold, all information received
from the Company or its Representatives, directly or indirectly, in confidence in accordance with
the Confidentiality Agreement.
Section
5.9 Notification of Certain Matters. The Company shall give prompt notice to Parent, and
Parent shall give prompt notice to the Company, of (i) any notice or other communication received
by such party from any Governmental Entity in connection with the Offer or the Merger or the other
transactions contemplated hereby or from any Person alleging that the consent of such Person is or
may be required in connection with the Offer or the Merger
49
or the other transactions contemplated hereby, (ii) any Actions commenced or, to such party’s
Knowledge, threatened against, relating to or involving or otherwise affecting such party or any of
its Subsidiaries which relate to the Offer or the Merger or the other transactions contemplated
hereby or (iii) the discovery of any fact or circumstance that, or the occurrence or non-occurrence
of any event the occurrence or non-occurrence of which, would cause or result in any of the
conditions to the Offer or the Merger set forth in Annex A or Article VI not being satisfied or
satisfaction of those conditions being materially delayed in violation of any provision of this
Agreement; provided, however, that the delivery of any notice pursuant to this Section 5.9 shall
not (x) cure any breach of, or non-compliance with, any other provision of this Agreement or (y)
limit the remedies available to the party receiving such notice; and, provided, further, that the
failure to give prompt notice hereunder pursuant to clause (iii) shall not constitute a failure of
a condition to the Offer or the Merger set forth in Annex A or Article VI except to the extent
that the underlying fact or circumstance not so notified would standing alone constitute such a
failure.
Section
5.10 Rule 16b-3. Prior to the Effective Time, the Company shall be permitted to take such steps
as may be reasonably necessary or advisable hereto to cause dispositions of Company equity
securities (including derivative securities) pursuant to the transactions contemplated by this
Agreement by each individual who is a director or officer of the Company to be exempt under Rule
16b-3 promulgated under the Exchange Act.
Section
5.11 Control of Operations. Without in any way limiting any party’s rights or obligations
under this Agreement, the parties understand and agree that (i) nothing contained in this Agreement
shall give Parent, directly or indirectly, the right to control or direct the Company’s operations
prior to the Effective Time, and (ii) prior to the Effective Time, the Company shall exercise,
consistent with the terms and conditions of this Agreement, complete control and supervision over
its operations.
Section
5.12 Certain Transfer Taxes. Any liability arising out of any real estate transfer Tax with
respect to interests in real property owned directly or indirectly by the Company or any of its
Subsidiaries immediately prior to the Merger, if applicable and due with respect to the Merger,
shall be borne by the Surviving Corporation and expressly shall not be a liability of stockholders
of the Company.
Section
5.13 Obligations of the Purchaser. Parent shall take all action necessary to cause the
Purchaser and the Surviving Corporation to perform their respective obligations under this
Agreement.
Section
5.14 Rule 14d-10(d) Matters. Prior to the Acceptance Time, the Company (acting through the
compensation committee of the Board of Directors) will take all such steps as may be required to
cause each agreement, arrangement or understanding entered into by the Company or the Company
Subsidiaries on or after the date hereof with any of its officers, directors or employees pursuant
to which consideration is paid to such officer, director or employee to be approved as an
“employment compensation, severance or other employee benefit arrangement” within the meaning of
Rule 14d-10(d)(1) under the Exchange Act and to satisfy the requirements of the non-exclusive safe
harbor set forth in Rule 14d-10(d) under the Exchange Act.
50
Section
5.15 Certain Professional Advisory Fees, etc. The Company will provide for the transfer,
promptly on or prior to the Acceptance Time, to the Company Financial Advisor of a cash amount
sufficient to pay in full all amounts due and payable to the Company Financial Advisor in
connection with the Offer and the transactions contemplated by this Agreement. The obligation of
the Company as set forth in this Section 5.15 shall survive the Effective Time and consummation of
the Offer and the Merger and shall be binding upon, and enforceable by the Company Financial
Advisor against, the Company’s successors and assigns.
Section
5.16 ISRA. If required under ISRA, prior to and after the Acceptance Time, the Company shall be
responsible for taking all necessary actions to comply with the requirements of ISRA with respect
to the transactions contemplated hereby, including, but not limited to, submitting all necessary
forms and conducting any required investigation and remediation, and the Company shall bear all of
the costs and expenses associated with such compliance, including without limitation, the filing of
a General Information Notice with the New Jersey Department of Environmental Protection (the
“NJDEP”) within five (5) days after the date hereof. Prior to and after the Closing, the
Company shall provide Parent with advance copies of all correspondence and documents to be filed in
connection with ISRA and shall incorporate all reasonable comments provided by Parent into such
filings.
Section
5.17 Fundamental Change Notice; Convertible Note Repurchase. Within thirty (30) days after the
Acceptance Time, the Company shall mail, or cause to be mailed, notice of the acceptance of, and
payment for, Shares pursuant to the Offer as a “Fundamental Change” to each holder of record of the
Convertible Notes in accordance with the terms of the Convertible Notes and each of the instruments
and other documents governing the Convertible Notes, including that certain Indenture dated as of
August 11, 2004 between the Company (f/k/a SFBC International, Inc.) and Wachovia Bank, National
Association, as Trustee (the “Indenture”), and the Company shall repurchase the Convertible
Notes from each holder of any Convertible Notes that exercises the Fundamental Change Repurchase
Right (as defined in the Convertible Notes) in accordance with the terms of the Convertible Notes,
the Indenture and each of the instruments and other documents governing the Convertible Notes.
ARTICLE VI
CONDITIONS TO CONSUMMATION OF THE MERGER
CONDITIONS TO CONSUMMATION OF THE MERGER
Section
6.1 Conditions to Each Party Under This Agreement. The respective obligations of each party to
consummate the Merger shall be subject to the satisfaction at or prior to the Effective Time of
each of the following conditions:
(a) This Agreement shall have been adopted and the Merger approved by the requisite vote of
the stockholders of the Company, if required by applicable Law.
(b) The Purchaser shall have accepted for payment, or caused to be accepted for payment, all
Shares validly tendered and not withdrawn in the Offer.
(c) The consummation of the Merger shall not then be restrained, enjoined or prohibited by any
Order of any Governmental Entity and there shall not be in effect any statute,
51
rule or regulation enacted, promulgated or deemed applicable to the Merger by any Governmental
Entity which prevents the consummation of the Merger.
ARTICLE VII
TERMINATION
TERMINATION
Section
7.1 Termination or Abandonment. Notwithstanding anything contained in this Agreement to
the contrary, this Agreement may be terminated and abandoned, whether before or after the Company
Stockholder Approval:
(a) by the mutual written consent of the Company and Parent, by their respective boards of
directors, at any time prior to the Effective Time;
(b) by either the Company or Parent, if:
(i) the Offer (as it may have been extended pursuant to Section 1.1) expires as a result of
the non-satisfaction of any condition to the Offer set forth in Annex A or is terminated or
withdrawn pursuant to its terms without any Shares being purchased thereunder; provided, however,
that the right to terminate this Agreement pursuant to this Section 7.1(b)(i) shall not be
available to any party whose breach of this Agreement has been the cause or resulted in the
non-satisfaction of any condition to the Offer set forth in Annex A or the termination or
withdrawal of the Offer pursuant to its terms without any Shares being purchased thereunder;
(ii) any Governmental Entity shall have issued an Order or taken any other action permanently
restraining, enjoining or otherwise prohibiting (i) prior to the Acceptance Time, the acceptance
for payment of, or payment for, Shares pursuant to the Offer or (ii) prior to the Effective Time,
the Merger, and such Order or other action shall have become final and nonappealable (which Order
or other action the party seeking to terminate this Agreement shall have used its reasonable best
efforts to resist, resolve or lift, as applicable, subject to the provisions of Section 5.4);
(iii) the Acceptance Time shall not have occurred on or before the Outside Date and the party
seeking to terminate this Agreement pursuant to this Section 7.1(b)(iii) shall not have breached in
any material respect its obligations under this Agreement in any manner that shall have proximately
caused the failure to consummate the Merger on or before the Outside Date;
(c) by the Company:
(i) if Parent or the Purchaser fails to commence (within the meaning of Rule 14d-2 under the
Exchange Act) the Offer as provided in Section 1.1 hereof within seven (7) Business Days after the
date hereof;
(ii) at any time prior to the Acceptance Time, if Parent or the Purchaser shall have breached
or failed to perform any of its representations, warranties, covenants or other agreements
contained in this Agreement, which breach or failure to perform cannot be cured by the Outside
Date, provided that the Company shall have given Parent and the Purchaser written notice, delivered
at least thirty (30) days prior to such termination, stating the
52
Company’s intention to terminate this Agreement pursuant to this Section 7.1(c)(ii) and the
basis for such termination; or
(iii) at any time following the 30th Business Day after having commenced the Offer
(within the meaning of Rule 14d-2 under the Exchange Act) as provided in Section 1.1 hereof and
prior to the Acceptance Time, in order to enter into a transaction that is a Superior Proposal, if,
prior to the Acceptance Time, (A) the Board of Directors determines that it has received a Superior
Proposal, (B) the Company has notified Parent in writing of its intention to terminate this
Agreement pursuant to this Section 7.1(c)(iii), and included with such notice the identity of the
Person making such proposal, the most current written agreements relating to the transaction that
constitutes such Superior Proposal and all related transaction agreements, (C) at least five (5)
Business Days following receipt by Parent of the notice referred to in clause (B) above, and taking
into account any revised proposal committed to by Parent since receipt of the notice referred to in
clause (B) above, the Board of Directors shall have determined in good faith, after consultation
with outside counsel and the Company’s financial advisor, that such Superior Proposal continues to
be more favorable to the stockholders of the Company from a financial point of view than the
revised proposal committed to by Parent, if any, (D) prior to or concurrently with such
termination, the Company pays the fee due under Section 7.2, and (E) concurrently with or
immediately following the termination of this Agreement pursuant to this Section 7.1(c)(iii), the
Company enters into a binding definitive transaction agreement with respect to such Superior
Proposal;
(d) by Parent, if:
(i) at any time prior to the Acceptance Time, the Company shall have breached or failed to
perform any of its representations, warranties, covenants or other agreements contained in this
Agreement, which breach or failure to perform (i) would result in a failure of a condition set
forth in paragraphs (c)(iii) or (iv) of Annex A to be satisfied and (ii) cannot be cured by the
Outside Date, provided that Parent shall have given the Company written notice, delivered at least
thirty (30) days prior to such termination, stating Parent’s intention to terminate this Agreement
pursuant to this Section 7.1(d)(i) and the basis for such termination;
(ii) at any time prior to the Acceptance Time, the Board of Directors or any committee thereof
(A) effects a Change of Recommendation, (B) fails to include in the Proxy Statement or the Schedule
14D-9 the Recommendation or (C) publicly approves or recommends any Alternative Proposal (it being
agreed that the taking by the Company or any of its Representatives of any of the actions permitted
by Section 5.2(c) shall not give rise to a right to terminate pursuant to this clause (ii));
(iii) at any time prior to the Acceptance Time, the Company gives Parent the notification
contemplated by Section 7.1(c)(iii); or
(iv) at any time prior to the Acceptance Time, any proceeding shall be commenced or any
petition shall be filed seeking relief with respect to the Company or any Significant Subsidiary
under any bankruptcy, insolvency or similar Law, which, in the case of any involuntary proceeding,
shall not have been vacated, discharged or dismissed within sixty
53
(60) days after the commencement of such proceeding; or the Company or any Significant
Subsidiary shall make any assignment for the benefit of creditors.
In the event of termination of this Agreement pursuant to this Section 7.1, this Agreement
shall forthwith become null and void and there shall be no liability or obligation on the part of
the Company, Parent, the Purchaser or their respective Subsidiaries or Affiliates, except that the
Confidentiality Agreement, Equity Funding Letter (as and to the extent provided therein) and the
provisions of Section 5.8, Section 7.2 and Article VIII will survive the termination hereof;
provided, however, that subject to Section 7.2(c), nothing herein shall relieve any party hereto
from liability for a deliberate and material breach of its covenants or agreements set forth in
this Agreement prior to such termination (which the parties acknowledge and agree shall not be
limited to reimbursement of expenses or out-of—pocket costs, and may include the benefit of the
bargain lost by the Company’s stockholders (taking into consideration relevant matters, including
the total amount payable to such stockholders under this Agreement and the time value of money),
which shall be deemed in such event to be damages of the Company).
Section
7.2 Termination Fees.
(a) In the event that:
(i) (A) a bona fide Alternative Proposal shall have been publicly disclosed after the date
hereof and not abandoned, and (B) following the occurrence of an event described in the preceding
clause (A), this Agreement is terminated by the Company or Parent pursuant to Section 7.1(b)(i) by
reason of a failure of the Minimum Condition, and (C) the Company consummates, or enters into a
definitive agreement providing for, an Alternative Proposal within twelve (12) months of the date
this Agreement is terminated (provided that for purposes of this Section 7.2(a)(i), the references
to “20%” in the definition of Alternative Proposal shall be deemed to be references to “50%”); or
(ii) this Agreement is terminated by the Company pursuant to Section 7.1(c)(iii); or
(iii) this Agreement is terminated by Parent pursuant to Section 7.1(d)(ii) or Section
7.1(d)(iii);
then in any such event under clause (i) or (ii) of this Section 7.2(a), the Company shall pay at
the direction of Parent to any Person that is a U.S. person for U.S. federal income tax purposes, a
termination fee of (x) six million dollars ($6,000,000) plus (y) the amount equal to all of
Parent’s actual and reasonably documented out-of-pocket fees and expenses (including reasonable
legal fees and expenses) actually incurred or paid by Parent or its Affiliates on or prior to the
termination of this Agreement in connection with the transactions contemplated by this Agreement
(the “Parent Expenses”), which amount shall in no event exceed three million dollars
($3,000,000), in cash (collectively, the “Termination Fee”), it being understood that in no
event shall the Company be required to pay the Termination Fee on more than one occasion.
(b) Any payment required to be made pursuant to clause (i) of Section 7.2(a) shall be made
promptly following the consummation of, or entry into a definitive agreement with respect to, the
transaction referred to therein, as the case may be (and in any event not later than
54
two (2) Business Days after delivery to the Company of notice of demand for payment after such
event); any payment required to be made pursuant to clause (ii) of Section 7.2(a) shall be made
concurrently with, and as a condition to the effectiveness of, the termination of this Agreement by
the Company pursuant to Section 7.1(c)(iii); and any payment required to be made pursuant to clause
(iii) of Section 7.2(a) shall be made promptly following termination of this Agreement by Parent
pursuant to Section 7.1(d)(ii) or Section 7.1(d)(iii), as applicable (and in any event not later
than two (2) Business Days after delivery to the Company of notice of demand for payment after such
event), and in each case such payment shall be made by wire transfer of immediately available funds
to an account to be designated by Parent.
(c) Each of the parties hereto acknowledges that the agreements contained in this Section 7.2
are an integral part of the transactions contemplated by this Agreement and that the Termination
Fee is not a penalty, but rather is liquidated damages in a reasonable amount that will compensate
Parent and the Purchaser, as the case may be, in the circumstances in which such Termination Fee is
payable for the efforts and resources expended and opportunities foregone while negotiating this
Agreement and in reliance on this Agreement and on the expectation of the consummation of the
transactions contemplated hereby, which amount would otherwise be impossible to calculate with
precision. Notwithstanding anything to the contrary in this Agreement, Parent’s right to receive
payment of the Termination Fee from the Company shall be the sole and exclusive remedy of Parent
and the Purchaser against the Company and its Subsidiaries and any of their respective former,
current or future officers, directors, partners, stockholders, managers, members, Affiliates or
agents for the loss suffered as a result of the failure of the Merger to be consummated, and upon
payment of such amount, none of the Company, any of its Subsidiaries or any of their respective
former, current or future officers, directors, partners, stockholders, managers, members,
Affiliates or agents shall have any further liability or obligation relating to or arising out of
this Agreement or the transactions contemplated hereby.
ARTICLE VIII
MISCELLANEOUS
MISCELLANEOUS
Section
8.1 No Survival of Representations and Warranties. None of the representations and
warranties in this Agreement or in any instrument delivered pursuant to this Agreement shall
survive the Acceptance Time. After the Acceptance Time, Parent and the Purchaser shall not be
permitted to claim that any breach by the Company of Section 5.1 results in a failure of a
condition to consummate the Merger pursuant to Article VI or excuses performance by Parent or the
Purchaser of any of its obligations hereunder. This Section 8.1 shall not limit any covenant or
agreement of the parties which by its terms contemplates performance after the Acceptance Time.
Section
8.2 Expenses. Except as otherwise set forth herein, whether or not the Merger is
consummated, all costs and expenses incurred in connection with the Offer, the Merger, this
Agreement and the transactions contemplated hereby shall be paid by the party incurring or required
to incur such expenses.
Section
8.3 Counterparts; Effectiveness. This Agreement may be executed in two or more
consecutive counterparts (including by facsimile), each of which shall be an original, with
55
the same effect as if the signatures thereto and hereto were upon the same instrument, and
shall become effective when one or more counterparts have been signed by each of the parties and
delivered (by telecopy or otherwise) to the other parties.
Section
8.4 Governing Law. This Agreement, and all claims or causes of action (whether at Law, in
contract or in tort) that may be based upon, arise out of or relate to this Agreement or the
negotiation, execution or performance hereof, shall be governed by and construed in accordance with
the Laws of the State of Delaware, without giving effect to any choice or conflict of Law provision
or rule (whether of the State of Delaware or any other jurisdiction) that would cause the
application of the Laws of any jurisdiction other than the State of Delaware.
Section
8.5 Jurisdiction; Enforcement. The parties agree that irreparable damage would occur in
the event that any of the provisions of this Agreement to be performed by any party were not
performed in accordance with their specific terms or were otherwise breached. It is accordingly
agreed that prior to the valid and effective termination of this Agreement in accordance with
Article VII, any party hereto shall be entitled to an injunction or injunctions to prevent breaches
of this Agreement and to enforce specifically the terms and provisions of this Agreement
exclusively in the Delaware Court of Chancery and any state appellate court therefrom within the
State of Delaware (or, if the Delaware Court of Chancery declines to accept jurisdiction over a
particular matter, any state or federal court within the State of Delaware). In addition, each of
the parties hereto irrevocably agrees that any legal action or proceeding with respect to this
Agreement and the rights and obligations arising hereunder, or for recognition and enforcement of
any judgment in respect of this Agreement and the rights and obligations arising hereunder brought
by the other party hereto or its successors or assigns, shall be brought and determined exclusively
in the Delaware Court of Chancery and any state appellate court therefrom within the State of
Delaware (or, if the Delaware Court of Chancery declines to accept jurisdiction over a particular
matter, any state or federal court within the State of Delaware). Each of the parties hereto
hereby irrevocably submits with regard to any such action or proceeding for itself and in respect
of its property, generally and unconditionally, to the personal jurisdiction of the aforesaid
courts and agrees that it will not bring any action relating to this Agreement or any of the
transactions contemplated by this Agreement in any court other than the aforesaid courts. Each of
the parties hereto hereby irrevocably waives, and agrees not to assert as a defense, counterclaim
or otherwise, in any action or proceeding with respect to this Agreement, (a) any claim that it is
not personally subject to the jurisdiction of the above named courts for any reason other than the
failure to serve in accordance with this Section 8.5, (b) any claim that it or its property is
exempt or immune from jurisdiction of any such court or from any legal process commenced in such
courts (whether through service of notice, attachment prior to judgment, attachment in aid of
execution of judgment, execution of judgment or otherwise) and (c) to the fullest extent permitted
by the applicable Law, any claim that (i) the suit, action or proceeding in such court is brought
in an inconvenient forum, (ii) the venue of such suit, action or proceeding is improper or (iii)
this Agreement, or the subject matter hereof, may not be enforced in or by such courts.
Section
8.6 WAIVER OF JURY TRIAL. EACH OF THE PARTIES HERETO IRREVOCABLY WAIVES ANY AND ALL RIGHT
TO TRIAL BY JURY IN ANY LEGAL
56
PROCEEDING BETWEEN THE PARTIES HERETO ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE
TRANSACTIONS CONTEMPLATED HEREBY.
Section
8.7 Notices. Any notice required to be given hereunder shall be sufficient if in writing,
and sent by facsimile transmission with electronic confirmation, by email, by reliable overnight
delivery service (with proof of service), by hand delivery or by certified or registered mail
(return receipt requested and first-class postage prepaid), addressed as follows:
To Parent or the Purchaser:
JLL PharmaNet Holdings, LLC
c/o JLL Partners, Inc.
000 Xxxxxxxxx Xxxxxx
00xx Xxxxx
Xxx Xxxx, XX 00000
Attention: Xxxxxx X. Xxxxx
Facsimile: (000) 000-0000
Email: X.Xxxxx@xxxxxxxxxxx.xxx
c/o JLL Partners, Inc.
000 Xxxxxxxxx Xxxxxx
00xx Xxxxx
Xxx Xxxx, XX 00000
Attention: Xxxxxx X. Xxxxx
Facsimile: (000) 000-0000
Email: X.Xxxxx@xxxxxxxxxxx.xxx
with a copy to: |
Skadden,
Arps, Slate, Xxxxxxx & Xxxx LLP Xxx Xxxxxx Xxxxxx X.X. Xxx 000 Xxxxxxxxxx, XX 00000-0000 Attention: Xxxxxx X. Xxxxxxx, Esq. Facsimile: (000) 000-0000 Email: xxxxxx.xxxxxxx@xxxxxxx.xxx |
To the Company: |
PharmaNet Development Group, Inc. 000 Xxxxxxxx Xxxxxx Xxxxxxxxx, XX 00000 Attention: Xxxxxxx X. XxXxxxxx Facsimile: (000) 000-0000 Email: xxxxxxxxx@xxxxxxxxx.xxx |
with copies to:
57
Xxxxxx & Xxxxxxx LLP 000 Xxxxx Xxxxxx Xxx Xxxx, XX 00000 Attention: Xxxxxxx X. Xxxxxx Xxxxx X. Xxxxxxxx Facsimile: (000) 000-0000 Email: xxxxxxx.xxxxxx@xx.xxx xxxxx.xxxxxxxx@xx.xxx |
and
|
||
Xxxxxx,
Xxxxx & Xxxxxxx LLP 000 Xxxxxxxx Xxxxxx Xxxxxxxxx, XX 00000-0000 Attention: Xxxxx Xxxxxx Facsimile: (000) 000-0000 Email: xxxxxxx@xxxxxxxxxxx.xxx |
or to such other address as any party shall specify by written notice so given, and such notice
shall be deemed to have been delivered as of the date so telecommunicated and confirmed, emailed,
overnight delivered, personally delivered or mailed. Any party to this Agreement may notify any
other party of any changes to the address or any of the other details specified in this Section
8.7; provided, however, that such notification shall only be effective on the date specified in
such notice or five (5) Business Days after the notice is given, whichever is later. Rejection or
other refusal to accept or the inability to deliver because of changed address, facsimile or email
of which no notice was given shall be deemed to be receipt of the notice as of the date of such
rejection, refusal or inability to deliver.
Section
8.8 Assignment; Binding Effect. Neither this Agreement nor any of the rights, interests
or obligations hereunder shall be assigned by any of the parties hereto (whether by operation of
Law or otherwise) without the prior written consent of the other parties, except that Parent and
the Purchaser may assign, in their sole discretion, any of or all of their rights, interest and
obligations under this Agreement to any of their Affiliates, but no such assignment shall relieve
the assigning party of its obligations hereunder. Subject to the preceding sentence, this
Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their
respective successors and assigns. Parent shall cause the Purchaser, and any assignee thereof, to
perform its obligations under this Agreement and shall be responsible for any failure of the
Purchaser or such assignee to comply with any representation, warranty, covenant or other provision
of this Agreement.
Section
8.9 Severability. Any term or provision of this Agreement which is invalid or
unenforceable in any jurisdiction shall, as to that jurisdiction, be ineffective to the extent of
such invalidity or unenforceability without rendering invalid or unenforceable the terms and
provisions of this Agreement in any other jurisdiction. If any provision of this Agreement is so
broad as to be unenforceable, such provision shall be interpreted to be only as broad as is
enforceable.
58
Section
8.10 Entire Agreement; No Third-Party Beneficiaries. This Agreement (including the
annexes, exhibits and letters hereto), the Confidentiality Agreement and the Equity Funding Letter
constitute the entire agreement, and supersede all other prior agreements and understandings, both
written and oral, between the parties with respect to the subject matter hereof and thereof and,
other than (a) the right of stockholders and holders of other securities to receive payment in
accordance with Article II after the Effective Time, (b) as set forth in Section 5.7 and (c) the
right of the Company, on behalf of its stockholders, to pursue damages in the event of Parent’s or
the Purchaser’s breach of this Agreement, is not intended to and shall not confer upon any Person
other than the parties hereto any rights or remedies hereunder.
Section
8.11 Amendments; Waivers. At any time prior to the Effective Time, any provision of this
Agreement may be amended or waived if, and only if, such amendment or waiver is in writing and
signed, in the case of an amendment, by the Company, Parent and the Purchaser, or in the case of a
waiver, by the party against whom the waiver is to be effective; provided, however, that after
receipt of the Company Stockholder Approval, if any such amendment or waiver shall by applicable
Law or in accordance with the rules and regulations of the Nasdaq require further approval of the
stockholders of the Company, the effectiveness of such amendment or waiver shall be subject to the
approval of the stockholders of the Company. Notwithstanding the foregoing, no failure or delay by
the Company or Parent in exercising any right hereunder shall operate as a waiver thereof nor shall
any single or partial exercise thereof preclude any other or further exercise of any other right
hereunder.
Section
8.12 Headings. Headings of the Articles and Sections of this Agreement are for convenience
of the parties only and shall be given no substantive or interpretive effect whatsoever. The table
of contents to this Agreement is for reference purposes only and shall not affect in any way the
meaning or interpretation of this Agreement.
Section
8.13 Interpretation. When a reference is made in this Agreement to an Article or Section,
such reference shall be to an Article or Section of this Agreement unless otherwise indicated.
Whenever the words “include,” “includes” or “including” are used in this Agreement, they shall be
deemed to be followed by the words “without limitation.” The words “hereof,” “herein” and
“hereunder” and words of similar import when used in this Agreement shall refer to this Agreement
as a whole and not to any particular provision of this Agreement. The word “or” shall be deemed to
mean “and/or.” All terms defined in this Agreement shall have the defined meanings when used in
any certificate or other document made or delivered pursuant thereto unless otherwise defined
therein. The definitions contained in this Agreement are applicable to the singular as well as the
plural forms of such terms and to the masculine as well as to the feminine and neuter genders of
such term. Any agreement, instrument or statute defined or referred to herein or in any agreement
or instrument that is referred to herein means such agreement, instrument or statute as from time
to time amended, modified or supplemented, including (in the case of agreements or instruments) by
waiver or consent and (in the case of statutes) by succession of comparable successor statutes and
references to all attachments thereto and instruments incorporated therein. Each of the parties
has participated in the drafting and negotiation of this Agreement. If an ambiguity or question of
intent or interpretation arises, this Agreement must be construed as if it is drafted by all the
parties, and no presumption or burden of proof shall arise favoring or disfavoring any party by
virtue of authorship of any of the provisions of this Agreement.
59
Section
8.14 Certain Definitions. For purposes of this Agreement, the following terms will have
the following meanings when used herein:
(a) “Affiliates” shall mean, as to any Person, any other Person which, directly or
indirectly, controls, or is controlled by, or is under common control with, such Person. As used
in this definition, “control” (including, with its correlative meanings, “controlled by” and “under
common control with”) shall mean the possession, directly or indirectly, of the power to direct or
cause the direction of management or policies of a Person, whether through the ownership of
securities or partnership or other ownership interests, by Contract or otherwise.
(b) “beneficial ownership” (and related terms such as “beneficially owned” or
“beneficial owner”) has the meaning set forth in Rule 13d-3 under the Exchange Act.
(c) “Business Day” shall mean any day other than a Saturday, Sunday or a day on which
the banks in New York, New York are authorized by Law or executive order to be closed.
(d) “Confidentiality Agreement” means the confidentiality agreement, dated December 1,
2008, by and between JLL Partners, Inc. and the Company Financial Advisor as representative of the
Company.
(e) “Contracts” means any contracts, agreements, licenses (or sublicenses), notes,
bonds, mortgages, indentures, commitments, leases (or subleases) or other instruments or
obligations, whether written or oral.
(f) “Convertible Notes” means the Company’s 2.25% Convertible Senior Notes Due 2024.
(g) “DGCL” means the General Corporation Law of the State of Delaware.
(h) “ISRA” means the New Jersey Industrial Site Recovery Act, N.J.S.A. 13:1-6K et
seq., as amended, and its implementing regulations.
(i) “Knowledge” means (i) with respect to Parent, the actual knowledge after due
inquiry of the individuals listed on Section 8.14(i)(i) of the Parent Disclosure Letter and (ii)
with respect to the Company, the actual knowledge after due inquiry of the individuals listed on
Section 8.14(i)(ii) of the Company Disclosure Letter.
(j) “on a fully diluted basis” means, as of any date, (i) the number of Shares
outstanding, plus (ii) the number of Shares the Company is then required to issue pursuant to
options, rights or other obligations outstanding at such date under any employee stock option or
other benefit plans or otherwise (assuming all options and other rights to acquire or obligations
to issue such Shares are fully vested and exercisable and all Shares issuable at any time have been
issued), including pursuant to the Company Stock Option Plans; provided, that Shares issuable with
respect to the Company Rights shall be excluded from such number; and provided further that Shares
issuable upon exercise, exchange or conversion of options, rights or other obligations as to which
the applicable exercise, exchange or conversion price exceeds the then
60
current market price of the Shares and the Offer Price pursuant to this Agreement shall be
excluded from such number.
(k) “Orders” means any orders, judgments, injunctions, awards, decrees, writs or other
legally enforceable requirement handed down, adopted or imposed by, including any consent decree,
settlement agreement or similar written agreement with, any Governmental Entity.
(l) “Other Antitrust Law” means the antitrust, foreign investment and competition
laws of all jurisdictions other than those of the United States.
(m) “Parent Group” means Parent and its Affiliates and Subsidiaries.
(n) “Parent Material Adverse Effect” means any fact, condition, circumstance, event,
change effect or occurrence that, individually or in the aggregate, prevents or materially delays
or materially impairs the ability of Parent and the Purchaser to consummate the Offer and the
Merger on a timely basis, or would reasonably be expected to do so.
(o) “Person” shall mean an individual, a corporation, a partnership, a limited
liability company, an association, a trust or any other entity, group (as such term is used in
Section 13 of the Exchange Act) or organization, including, without limitation, a Governmental
Entity, and any permitted successors and assigns of such person.
(p) “Solvent” means as of any date of determination, (a) the amount of the fair
saleable value of the assets of the Company and its Subsidiaries, taken as a whole, exceeds, as of
such date, the sum of (i) the value of all liabilities of the Company and its Subsidiaries, taken
as a whole, including contingent and other liabilities, as of such date, as such quoted terms are
generally determined in accordance with the applicable federal Laws governing determinations of the
solvency of debtors, and (ii) the amount that will be required to pay the probable liabilities of
the Company and its Subsidiaries, taken as a whole, on their existing debts (including contingent
liabilities) as such debts become absolute and matured; (b) the Company will not have, as of such
date, an unreasonably small amount of capital for the operation of the business in which it is
engaged or proposed to be engaged following such date; and (c) the Company will be able to pay its
liabilities, including contingent and other liabilities, as they mature.
(q) “Subsidiaries” of any party shall mean any corporation, partnership, association,
trust or other form of legal entity of which (i) more than 50% of the outstanding voting securities
(or other voting interests or, if there are no voting interests, equity interests) are directly or
indirectly owned by such party, or (ii) such party or any Subsidiary of such party is a general
partner (excluding partnerships in which such party or any Subsidiary of such party does not have a
majority of the voting interests in such partnership), and, with respect to the Company, shall
include SFBC Anapharm Europe, S.L.
(r) Each of the following terms is defined on the page set forth opposite such term:
409A Plan |
25 | |||
Acceptance Time |
6 |
61
Acquiring Person |
32 | |||
Action |
48 | |||
Actions |
26 | |||
Affiliate Transaction |
26 | |||
Affiliates |
60 | |||
Agreement |
1 | |||
Alternative Proposal |
43 | |||
Board of Directors |
1 | |||
Book-Entry Shares |
13 | |||
Business Day |
60 | |||
Cancelled Shares |
12 | |||
Certificate of Merger |
7 | |||
Certificates |
13 | |||
Change of Recommendation |
42 | |||
Closing |
7 | |||
Closing Date |
7 | |||
Code |
13 | |||
Company |
1 | |||
Company Approvals |
20 | |||
Company Benefit Plan |
24 | |||
Company Charter |
8 | |||
Company Common Stock |
1 | |||
Company Disclosure Letter |
17 | |||
Company Employment Agreement |
29 | |||
Company Financial Advisor |
32 | |||
Company Material Adverse Effect |
17 | |||
Company Meeting |
9 | |||
Company Rights |
1 | |||
Company SEC Documents |
21 | |||
Company Stock Option |
15 | |||
Company Stockholder Approval |
30 | |||
Confidentiality Agreement |
60 | |||
Continuing Directors |
6 | |||
Contracts |
60 | |||
Convertible Notes |
10,60 | |||
DGCL |
60 | |||
Dissenting Shares |
11 | |||
Dissenting Stockholders |
11 | |||
Distribution Date |
32 | |||
Effective Time |
8 | |||
Environmental Law |
23 | |||
Equity Funding Letter |
35 | |||
Equity Plans |
15 | |||
ERISA |
24 | |||
ERISA Affiliate |
25 | |||
ESPP |
16 |
62
Exchange Act |
2 | |||
Exchange Fund |
13 | |||
Expiration Date |
3 | |||
Filed SEC Documents |
17 | |||
Final Date |
16 | |||
Foreign Company Benefit Plan |
25 | |||
Fundamental Change |
51 | |||
GAAP |
22 | |||
Governmental Entity |
20 | |||
Hazardous Substance |
23 | |||
HSR Act |
20 | |||
Indebtedness |
38 | |||
Indemnified Party |
48 | |||
Indenture |
51 | |||
Initial Expiration Date |
3 | |||
Intellectual Property |
29 | |||
IRS |
24 | |||
ISRA |
60 | |||
JLL Funds |
35 | |||
Knowledge |
60 | |||
Laws |
22 | |||
Lien |
21 | |||
Material Contract |
31 | |||
Merger Consideration |
12 | |||
Minimum Condition |
2 | |||
Nasdaq |
6 | |||
NJDEP |
51 | |||
Offer |
1 | |||
Offer Documents |
4 | |||
Offer Price |
1 | |||
Offer to Purchase |
2 | |||
on a fully diluted basis |
60 | |||
Orders |
61 | |||
Other Antitrust Law |
61 | |||
Outside Date |
3 | |||
Parent Approvals |
34 | |||
Parent Disclosure Letter |
33 | |||
Parent Disclosure Letter |
33 | |||
Parent Expenses |
54 | |||
Parent Group |
61 | |||
Paying Agent |
13 | |||
Permits |
22 | |||
Promissory Note |
11 | |||
Proxy Statement |
9 | |||
Purchaser |
1 | |||
Purchaser Material Adverse Effect |
61 |
63
Recommendations |
1 | |||
Representatives |
40 | |||
Rights Agreement |
1 | |||
RSU Award |
15 | |||
RSU Consideration |
15 | |||
Xxxxxxxx-Xxxxx Act |
21 | |||
Schedule 14D-9 |
5 | |||
Schedule TO |
4 | |||
SEC |
3 | |||
Securities Act |
21 | |||
Shares |
1 | |||
Short Form Threshold |
10 | |||
Significant Subsidiary |
19 | |||
Solvent |
61 | |||
Stock Acquisition Date |
32 | |||
Subsidiaries |
61 | |||
Superior Proposal |
43 | |||
Surviving Corporation |
7 | |||
Takeover Statute |
5 | |||
Tax Return |
28 | |||
Taxes |
28 | |||
Termination Date |
37 | |||
Termination Fee |
54 | |||
Top-Up Closing |
11 | |||
Top-Up Exercise Notice |
10 | |||
Top-Up Notice Receipt |
11 | |||
Top-Up Option |
10 | |||
Top-Up Shares |
10 |
[Signature page follows]
64
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and
delivered as of the date first above written.
JLL PHARMANET HOLDINGS, LLC |
||||
By: | /s/ Xxxx X. Xxxx | |||
Name: | Xxxx X. Xxxx | |||
Title: | President | |||
PDGI ACQUISITION CORP. |
||||
By: | /s/ Xxxxx Xxxxxxxxx | |||
Name: | Xxxxx Xxxxxxxxx | |||
Title: | Vice President and Secretary | |||
PHARMANET DEVELOPMENT GROUP, INC. |
||||
By: | /s/ Xxxxxxx X. XxXxxxxx | |||
Name: | Xxxxxxx X. XxXxxxxx | |||
Title: | President and Chief Executive Officer | |||
ANNEX A
Conditions to the Offer
Conditions to the Offer
Notwithstanding any other provisions of the Offer and in addition to the Purchaser’s rights to
extend, amend or terminate the Offer in accordance with the provisions of the Merger Agreement and
applicable Law, the Purchaser shall not be required to accept for payment or, subject to any
applicable rules and regulations of the SEC including Rule 14e-1(c) promulgated under the Exchange
Act, pay for any validly tendered Shares and may delay the acceptance for payment of or, subject to
the restrictions referred to above, the payment for, any validly tendered Shares, if (a) the
Minimum Condition shall not have been satisfied at the Expiration Date, (b) any waiting period
under the HSR Act applicable to the transactions contemplated by the Merger Agreement has not
expired or terminated at or prior to the Expiration Date (the “HSR Condition”), or (c) any
of the following conditions exist or has occurred and is continuing at the Expiration Date:
(i) there shall be pending any suit, action or proceeding by any Governmental Entity of
competent jurisdiction against Parent, the Purchaser, the Company or any Company Subsidiary
challenging the acquisition by Parent or the Purchaser of any Shares pursuant to the Offer or
seeking to make illegal, restrain or prohibit the making or consummation of the Offer or the
Merger;
(ii) there shall be any statute, rule, regulation or Order enacted, entered, enforced,
promulgated or which is deemed applicable pursuant to an authoritative interpretation by or on
behalf of a Government Entity of competent jurisdiction to the Offer, the Merger or any other
transaction contemplated by the Merger Agreement, or any other action shall be taken by any
Governmental Entity, other than the application to the Offer or the Merger of applicable waiting
periods under the HSR Act, that (x) is, in the reasonable judgment of Parent and the Purchaser,
likely to result, directly or indirectly, in any of the consequences referred to in paragraph (i)
above, or (y) has the effect of making the Offer, the Merger or any other transaction contemplated
by the Merger Agreement illegal or which has the effect of prohibiting or otherwise preventing the
consummation of the Offer, the Merger or any other transaction contemplated by the Merger
Agreement;
(iii) (A) any representation or warranty of the Company contained in the Merger Agreement
(without giving effect to any references to any Company Material Adverse Effect or materiality
qualifications and other qualifications based upon the concept of materiality or similar phrases
contained therein) shall fail to be true and correct in any respect as of the date of the Merger
Agreement or as of the Expiration Date with the same force and effect as if made on and as of such
date, except for representations and warranties that relate to a specific date or time (which need
only be true and correct as of such date or time), except as have had, individually or in the
aggregate with all other failures to be true or correct, a Company Material Adverse Effect;
(iv) the Company shall have breached or failed, in any material respect, to perform or to
comply with any agreement or covenant to be performed or complied with by it under the Merger
Agreement and such breach or failure shall not have been cured;
A-1
(v) since the date of the Merger Agreement, any fact(s), circumstance(s), event(s), change(s),
effect(s) or occurrence(s) shall have occurred, which has had or would be reasonably expected to
have, individually or in the aggregate, a Company Material Adverse Effect;
(vi) the Purchaser shall have failed to receive a certificate of the Company, executed by the
Chief Executive Officer and the Chief Financial Officer of the Company, dated as of the Expiration
Date, to the effect that the conditions set forth in paragraphs (iii) and (iv) of this Annex A have
not occurred; or
(vii) the Merger Agreement shall have been terminated in accordance with its terms.
The foregoing conditions (including those set forth in clauses (a), (b) and (c) of the initial
paragraph) are for the sole benefit of Parent and the Purchaser and may be asserted by Parent or
the Purchaser regardless of the circumstances giving rise to any such conditions and may be waived
by Parent or the Purchaser in whole or in part at any time and from time to time in their sole
discretion, in each case subject to the terms of the Merger Agreement. Any reference in this Annex
A or the Merger Agreement to a condition or requirement being satisfied shall be deemed to be
satisfied if such condition or requirement is waived in accordance with the prior sentence hereto.
The foregoing conditions shall be in addition to, and not a limitation of, the rights of Parent and
the Purchaser to extend, terminate, amend and/or modify the Offer pursuant to the terms and
conditions of the Merger Agreement. The failure by Parent or the Purchaser at any time to exercise
any of the foregoing rights shall not be deemed a waiver of any such right and each such right
shall be deemed an ongoing right which may be asserted at any time and from time to time.
The capitalized terms used in this Annex A and not defined in this Annex A shall have the
meanings set forth in the Agreement and Plan of Merger (the “Merger Agreement”), dated as
of February 3, 2009, by and among JLL PharmaNet Holdings, LLC, PDGI Acquisition Corp. and PharmaNet
Development Group, Inc.
A-2